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Hepatocellular carcinoma (HCC) is the second leading cause of death for 
cancer worldwide. Several studies on hepatocellular carcinoma epidemiology 
linked this malignancy with obesity and metabolic disorders. However, little is 
known about the molecular mechanisms responsible for this connection. The 
main purpose of this thesis is to elucidate the role of Jnk1 and Ppara, two 
important metabolic genes, in hepatocellular carcinoma development.  
Adipose tissue is the most important organ for lipid storage; during obesity it 
undergoes to a substantial remodeling. JNK1 is known to control IL-6 
production in the adipose tissue during obesity and its depletion in adipocyte 
protects against liver steatosis, a predisposing factor for HCC development. We 
demonstrate that adipose tissue JNK1 in normal diet can trigger hepatocellular 
carcinoma development. In fact, the deletion of JNK1 in adipose tissue 
increases circulating levels of adiponectin, which in turn activates AMPKα and 
p38α in hepatocytes, protecting against chemical-induced tumor development. 
Our results highlight the relevance of adipose tissue in liver cancer development 
and the central role that JNK1 plays in this crosstalk. 
PPARα is a nuclear receptor of fatty acids. It is highly expressed in the liver and 
obesity induces its activation. However, PPARα role in liver carcinogenesis is 
controversial. Here we show that PPARα activation promotes obesity-
associated hepatic cancer. Mice lacking PPARα are protected against chemical-
induced hepatocellular carcinoma when fed a high fat diet. Additionally, bone 
marrow transplantation experiments reveal no significant contribution of 
inflammatory cells, suggesting a cell-autonomous function of PPARα in 
hepatocytes. Hepatic PPARα activation, induced by Jnk1 and Jnk2 deletion, is 
sufficient to cause spontaneous liver cancer, confirming a central role of PPARα 
activation in liver tumorigenesis. Our results provide a molecular mechanism 
linking metabolic disorders with liver cancer, emphasizing a central role for 
PPARα in the connection.  
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El carcinoma hepatocelular es la segunda causa de muerte por cáncer en el 
mundo. Estudios epidemiológicos relacionan el carcinoma hepatocelular con la 
obesidad y los trastornos metabólicos. Sin embargo los mecanismos 
moleculares que controlan esta conexión no están del todo aclarados. El 
objetivo principal de esta tesis es determinar el papel de Jnk1 y Ppara, dos 
importantes genes metabólicos, en el desarrollo del carcinoma hepatocelular. 
El tejido adiposo es el órgano más importante para el almacenamiento de los 
lípidos, sufriendo una considerable remodelación durante la obesidad. JNK1 es 
una proteína quinasa activada por estrés que controla la producción de IL-6 por 
parte del tejido adiposo durante la obesidad. Nuestros resultados demuestran 
que JNK1 en el tejido adiposo puede facilitar el desarrollo del carcinoma 
hepático en animales alimentados con dieta no grasa. De hecho, la eliminación 
de JNK1 en el tejido adiposo induce el aumento de los niveles circulantes de 
adiponectina. Esta adipoquina activa AMPKα y p38α en los hepatocitos, 
protegiendo del desarrollo del tumor hepático inducido por compuestos 
químicos carcinógenos. Nuestros resultados destacan la importancia del tejido 
adiposo en el desarrollo del carcinoma hepatocelular y el papel central que 
JNK1 ejerce en la comunicación entre el tejido adiposo y el hepatocito. 
PPARα es un receptor nuclear de ácidos grasos. Está altamente expresado en 
el hígado, y la obesidad induce su activación. Sin embargo, no se conoce en la 
actualidad el papel de PPARα en la carcinogénesis hepática. En esta tesis 
demostramos que la activación de PPARα facilita el desarrollo del cáncer 
hepático en animales alimentados con dieta grasa. Ratones carentes en 
PPARα están protegidos frente al desarrollo del carcinoma hepatocelular 
inducido por carcinógenos químicos cuando son alimentados con dieta grasa. 
Además, experimentos de trasplante de medula ósea revelan que la 
contribución de las células inflamatoria no es significativa, sugiriendo que la 
función de PPARα es propia del hepatocito. La activación hepática de PPARα 
inducida por la supresión de Jnk1 y Jnk2, es suficiente para causar cáncer 
hepático espontáneamente, confirmando el papel central de la activación de 
PPARα en el desarrollo del carcinoma hepático. Nuestros resultados aportan 
un mecanismo molecular que conecta los trastornos metabólicos con el cáncer 
hepático, resaltando un papel central de PPARα en esta relación. 
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INDEX 
  
 
 
  
INDEX 
19 
 
LIST OF CONTENTS 
 
ABSTRACT ................................................................................................................................. 9 
PRESENTACIÓN ..................................................................................................................... 13 
INDEX ........................................................................................................................................ 17 
LIST OF CONTENTS ...................................................................................................... 19 
LIST OF FIGURES AND TABLES ................................................................................ 22 
ABBREVIATIONS ................................................................................................................... 25 
INTRODUCTION ..................................................................................................................... 37 
1. INFLAMMATION AND CANCER ............................................................................ 39 
1.1 Obesity, metabolic syndrome and cancer .................................................................. 40 
2. LIVER CANCER .......................................................................................................... 42 
2.1 Hepatocellular carcinoma .......................................................................................... 43 
2.2 Obesity, inflammation and HCC ............................................................................... 44 
3. METABOLIC GENES ................................................................................................. 46 
3.1 Stress-activated protein kinases................................................................................. 46 
3.1.1 c-Jun N-terminal kinases .................................................................................... 46 
3.1.2 JNKs in HCC ...................................................................................................... 48 
3.1.3 JNK in metabolism ............................................................................................. 49 
3.2 Peroxisome proliferator-activated receptors ............................................................. 49 
3.2.1 PPARα ................................................................................................................ 50 
3.2.2 PPARα in metabolism ........................................................................................ 51 
3.2.3 PPARα in inflammation ..................................................................................... 52 
3.2.4 PPARα and HCC development .......................................................................... 53 
OBJECTIVES ........................................................................................................................... 55 
MATERIALS AND METHODS.............................................................................................. 59 
1. ROLE OF JNK1 IN ADIPOSE TISSUE-LIVER CROSSTALK IN HCC 
DEVELOPMENT.............................................................................................................. 61 
Animals ........................................................................................................................... 61 
Cell culture ...................................................................................................................... 63 
Retrovirus production ...................................................................................................... 63 
Xenograft ......................................................................................................................... 64 
Metabolomics .................................................................................................................. 64 
Metabolite extraction and derivatization. .................................................................... 64 
Quality Control (QC) .................................................................................................. 64 
INDEX 
20 
 
GC-MS analysis .......................................................................................................... 65 
GC-MS and LC-MS data treatment and metabolite identification .............................. 66 
Statistical analysis ....................................................................................................... 67 
Validation of the PLS-DA model ................................................................................ 67 
Histology ......................................................................................................................... 68 
Real Time qPCR.............................................................................................................. 68 
Luminex .......................................................................................................................... 68 
Biochemical analysis ....................................................................................................... 68 
RNA-sequencing ............................................................................................................. 69 
Statistical analysis ........................................................................................................... 69 
2. ROLE OF PPARα ACTIVATION IN LIVER CANCER ......................................... 71 
Animals ........................................................................................................................... 71 
Serum analysis ................................................................................................................ 72 
Biochemical analysis ....................................................................................................... 72 
Histochemistry ................................................................................................................ 72 
Real time q-PCR.............................................................................................................. 73 
Statistical analysis ........................................................................................................... 73 
RESULTS................................................................................................................................... 77 
1. ROLE OF JNK1 IN ADIPOSE TISSUE-LIVER CROSSTALK IN HCC 
DEVELOPMENT ................................................................................................................. 79 
1.1 JNK1 deficiency in adipose tissue does not protect against HCC in HFD.................... 82 
1.2 JNK1 deficiency in adipose tissue protects against HCC in normal diet ...................... 84 
1.3 Different metabolites profile in F
WT
 and F
KO
 blood ...................................................... 85 
1.4 JNK1 deficiency in adipose tissue protects against xenograft tumor development ...... 87 
1.5 Jnk1 deletion in adipose tissue does not influence liver regeneration ........................... 88 
1.6 Adipose tissue lacking JNK1 is functional and presents normal infiltration levels ...... 88 
1.7 Increased circulating adiponectin in F
KO
 mice .............................................................. 91 
1.8 Adiponectin depletion reverts the phenotype of F
KO
 mice. ........................................... 92 
1.9 Adiponectin signaling is induced in livers from F
KO
 mice ............................................ 94 
1.10 AMPKα activation inhibits tumor growth ................................................................... 96 
1.11 Constitutive active p38α blocks tumor growth ........................................................... 96 
1.12 RNA-sequencing reveals TRAIL as another possible mediator of tumor protection .. 97 
2. ROLE OF PPARα ACTIVATION IN LIVER CANCER ........................................... 103 
2.1 PPARα deficiency protects against DEN-induced HCC development in HFD-fed mice
 ........................................................................................................................................... 105 
2.2 Lack of PPARα does not influence liver regeneration ................................................ 108 
INDEX 
21 
 
2.3 Ppara
 
deletion protects from liver damage on HFD ................................................... 109 
2.4 Lack of PPARα protects against HCC independently of bone marrow. ..................... 113 
2.5 PPARα deficiency inhibits hepatocyte proliferation ................................................... 114 
2.6 PPARα hyperactivation in hepatocytes promotes liver cancer ................................... 116 
DISCUSSION .......................................................................................................................... 121 
1. ROLE OF JNK1 IN ADIPOSE TISSUE-LIVER CROSSTALK IN HCC 
DEVELOPMENT............................................................................................................ 123 
1.1 IL-6 produced by adipose tissue is not relevant for DEN-induced HCC ................ 123 
1.2 ND-F
KO
 mice are protected against HCC development and have normal liver 
regeneration after partial hepatectomy .......................................................................... 125 
1.3 Different metabolic profile in F
WT
 and F
KO
 mice .................................................... 126 
1.4 Adipose tissue from F
KO
 mice is functional ............................................................ 126 
1.5 Adiponectin protects against HCC development .................................................... 127 
1.6 Adipose tissue RNAseq reveals TRAIL as another mediator in tumor protection . 128 
2. ROLE OF PPARα ACTIVATION IN LIVER CANCER ....................................... 131 
2.1 PPARα activation is necessary for HCC development during obesity.................... 131 
2.2 Ppara
-/-
 mice are protected against DEN-induced liver damage .............................. 132 
2.3 PPARα induces HCC development in HFD in a cell-autonomous way .................. 132 
2.4 PPARα activation induces uncontrolled proliferation ............................................. 133 
2.5 PPARα hyperactivation promotes liver cancer ....................................................... 133 
CONCLUSIONS ..................................................................................................................... 137 
CONCLUSIONES ................................................................................................................... 141 
REFERENCES ........................................................................................................................ 145 
  
INDEX 
22 
 
LIST OF FIGURES AND TABLES 
 
Figure I1. Cancer Incidence Age-Standardized Rate in both sexes. .......................................... 39 
Figure I2. Liver Cancer Incidence  and Mortality. ..................................................................... 43 
Figure I3. Mortality from Cancer According to Body-Mass Index for U.S. Men and Women in 
the Cancer Prevention Study II, 1982 through 1998. .................................................................. 44 
Figure I4. Progression from Healthy Liver to Hepatocellular Carcinoma. ................................ 45 
Figure I5. Schematic representation of JNKs pathways. ........................................................... 47 
Figure I6. Schematic representation of PPARs activation. ........................................................ 51 
Figure M1. Schematic representation of mouse lines crossing to generate F
WT
 and F
KO 
mice. . 61 
Figure M2. Schematic representation of mouse lines crossing to generate F
WT
Adipoq
-/-
 and F
KO
 
Adipoq
-/-
 mice. ............................................................................................................................. 62 
TABLE I. qRT-PCR primers...................................................................................................... 70 
TABLE II. qRT-PCR primers .................................................................................................... 74 
Figure R1. JNK1 expression analysis in organs from F
WT
 and F
KO
 mice. ................................. 82 
Figure R2. Effect of adipose tissue JNK1 deficiency on HCC in HFD-fed mice. ..................... 83 
Figure R3. Effect of adipose tissue JNK1 deficiency on HCC in ND-fed mice. ....................... 84 
Figure R4. Metabolomics analysis of serum from DEN-treated F
WT
 and F
KO
 mice. ................. 86 
Figure R5. Hep53.4 cells xenograft in ND-fed F
WT
 and F
KO
 mice. ............................................ 87 
Figure R6. Liver regeneration after partial hepatectomy in ND-fed F
WT
 and F
KO
 mice. ........... 88 
Figure R7. Body weight and white adipose tissue analysis of ND-fed F
WT
 and F
KO
 mice. ....... 89 
Figure R8. Macrophage infiltration in white adipose tissue and circulating cytokines analysis in 
ND-fed F
WT 
and F
KO
 mice. .......................................................................................................... 91 
Figure R9. Circulating adiponectin levels in ND-fed F
WT
 and F
KO
 mice. .................................. 92 
Figure R10. Hep53.4 cells xenograft in F
WT
Adipoq
-/-
 and F
KO
Adipoq
-/-
 mice. ........................... 93 
Figure R11. HCC development in F
WT
Adipoq
-/-
 and F
KO
Adipoq
-/-
. ............................................ 94 
Figure R12. Adiponectin signaling in liver from F
WT
 and F
KO
 after DEN treatment ................. 95 
Figure R13. Hep53.4 cells xenograft in water or metformin treated C57BL/6J mice. .............. 96 
Figure R14. Hep53.4 cells xenograft treated with retrovirus expressing p38α constitutively 
active form. ................................................................................................................................. 97 
Figure R15. Adipose tissue RNA-sequencing from ND-fed F
WT
 and F
KO
 mice. ....................... 98 
Figure R16. qRT-PCR RNA-seq validation of Tnfsf10, Serpine1 and Rasal2 in adipose tissue 
from ND-fed F
WT 
and F
KO
. .......................................................................................................... 99 
Figure R17. TRAIL signaling analysis in livers from ND-fed F
WT
 and F
KO
 mice. .................. 100 
Figure R18. FLIP expression analysis in tumors from ND-fed F
WT
 and F
KO
 mice. ................. 100 
Figure R19. Effect of PPARα deficiency on HCC in ND-fed animals .................................... 106 
Figure R20. Effect of PPARα deficiency on HCC in HFD-fed animals .................................. 107 
INDEX 
23 
 
Figure R21. Liver regeneration after partial hepatectomy in HFD-fed WT and Ppara
-/-
 mice.108 
Figure R22. Liver damage analysis after acute DEN treatment on HFD-fed WT and  Ppara
-/-
 
mice. .......................................................................................................................................... 109 
Figure R23. Signaling analysis in acute DEN-treated HFD-fed in WT and Ppara
-/-
 mice. ..... 110 
Figure R24. Circulating cytokines after acute DEN treatment of HFD-fed WT and Ppara
-/-
 
mice. .......................................................................................................................................... 111 
Figure R25. Liver and tumor infiltration and cytokines production in chronic-DEN treated 
HFD-fed WT and Ppara
-/-
 mice. ............................................................................................... 112 
Figure R26. Lipid peroxidation analysis in livers from HFD-fed WT and Ppara
-/-
 mice. ....... 113 
Figure R27. HCC development in HFD-fed chimera mice. ..................................................... 114 
Figure R28. Cell signaling analysis of livers and tumors from chronic-DEN treated HFD-fed 
WT and Ppara
-/-
 mice. ............................................................................................................... 115 
Figure R29. Cell cycle regulators analysis in livers and tumors from chronic-DEN treated 
HFD-fed WT and Ppara
-/-
 mice. ............................................................................................... 116 
Figure R30. Histological analysis of 10-month-old ND-fed LWT and LDKO mice. .............. 117 
Figure R31. Analysis of 14-month-old ND-fed LWT and LDKO mice. ................................. 118 
Figure D1. Schematic representation of the role of JNK1 in adipose tissue-liver crosstalk during 
HCC development. .................................................................................................................... 130 
Figure D2. Schematic representation of the role of PPARα activation in liver cancer. ........... 135 
  
  
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
  
 
  
ABBREVIATIONS 
27 
 
A 
 
Acc1 Acetyl-coenzyme A carboxylase 1 gene 
Acox1 Peroxisomal acyl-coenzyme A oxidase 1 
Adipoq Adiponectin gene 
AdipoR1 Adiponectin receptor 1 
AdipoR2 Adiponectin receptor 2 
AKT Protein kinase B 
Alb Albumin 
ALT Alanine aminotransferase 
AMDIS Automated mass spectrometry deconvolution and identification system 
AMP Adenosine monophosphate 
AMPK AMP-activated protein kinase 
ANOVA Analysis of variance 
AP-1 Activator protein 1 
APO-CIII Apolipoprotein C3 
AST Aspartate aminotransferase 
ATM Adipose Tissue Macrophages 
 
B  
BM Bone marrow 
BMI Body mass index 
BSTFA N,O-Bis(trimethylsilyl)trifluoroacetamide 
 
C  
cAMP Cyclic AMP 
Cas9 Crispr-associated protein 9 
CBP/p300 CREB-binding protein 
CCL2 Chemokine (C-C motif) ligand 2 
ABBREVIATIONS 
28 
 
CCL3 Chemokine (C-C motif) ligand 3 
Ccna1 Cyclin A1 gene 
Cdc25c M-phase inducer phosphatase 3 gene 
CD-HFD Choline deficient-high fat diet 
Cdk2 Cyclin-dependent kinase 2 gene 
c-Fos Cellular Fos 
c-Jun Cellular Jun 
c-Myc Cellular Myc 
Cpt-I Carnitine palmitoyltransferase I 
Cpt-II Carnitine palmitoyltransferase II 
CREB cAMP response element binding 
CRISPR Clustered regularly interspaced short palindromic repeats 
CXCL2 Chemokine (C-X-C motif) ligand 2 
 
D  
DEN Diethylnitrosamine 
DMEM Dulbecco's modified Eagle's medium 
DNA Deoxyribonucleic acid 
DNAse Deoxyribonuclease 
 
E  
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid 
Ehhadh  Peroxisomal bifunctional enzyme gene 
Elane Elastase gene 
ELISA Enzyme-linked immunosorbent assay 
Emr1 f4/80 gene 
ER Endoplasmic reticulum 
ABBREVIATIONS 
29 
 
ERKs Epithelial signal-regulated kinases 
ESI Electrospray ionization 
 
F  
FA Fatty acids 
FABP Fatty acid-binding protein 
Fabp4 Fatty acid binding protein 4 
Fas Fatty acids synthase gene 
FBS Fetal bovine serum 
FFA Free Fatty Acids 
Fgf21 Fibroblast growth factor 21 
FKO Fabp4Cre+Jnk1f/- 
FLICE FADD-like IL-1β-converting enzyme 
FLIP FLICE-inhibitory protein 
Foxm1 Forkhead box protein M1 gene 
FWT Fabp4Cre+Jnk1+/- 
 
G  
Gapdh Glyceraldehyde 3-phosphate dehydrogenase 
GC-MS Gas chromatography-mass spectrometry 
 
H  
HBV Hepatitis B Virus 
HCC Hepatocellular carcinoma 
HCV Hepatitis C Virus 
HFD High fat diet 
Hif1α Hypoxia-inducible factor 1-alpha gene 
HMW High molecular weight 
ABBREVIATIONS 
30 
 
I 
 
i.d. Internal diameter 
i.p. Intraperitoneal 
IFNγ Interferon γ 
IL-10 Interleukin 10 
IL-12 Interleukin 12 
IL-1β Interleukin 1 β 
IL-6 Interleukin 6 
iNos Inducible nitric oxide synthase 
IRS Insulin receptor substrate 
IS Internal standard 
i.v. Intravenous 
 
J  
JAK Janus Kinase 
JNK c-Jun N-terminal kinase 
JNK1 c-Jun N-terminal kinase 1 
JNK2 c-Jun N-terminal kinase 2 
JNK3 c-Jun N-terminal kinase 3 
 
L  
Lcad Long-chain acyl-CoA dehydrogenase 
LC-MS Liquid chromatography-Mass spectrometry 
L-FABP Liver-type fatty acid-binding protein 
LMW Low molecular weight 
LoxP Locus of X-over P1 
LPL Lipoprotein lipase 
LPS Lipopolysaccharide  
ABBREVIATIONS 
31 
 
LTB4 Leukotriene B4 
Lyz2 Lysozyme gene 
 
M  
MAPK Mitogen-activated protein kinases 
Mcad Medium-chain acyl-CoA dehydrogenase 
MEK MAPK/ERK kinase 
MKK4 MAP kinase kinase 4 
MKK7 MAP kinase kinase 7 
M-MLV Moloney Murine Leukemia Virus 
mRNA Messenger RNA 
MS Mass spectrometry 
MSD Macromolecular structure database 
mTOR Mammalian target of rapamycin 
mTORC1 Mammalian target of rapamycin complex 1 
 
N  
NAFLD Non-alcoholic fatty liver disease 
NASH Non-alcoholic steatohepatitis 
NCoR/SMRT 
Nuclear receptor co-repressor/silencing mediator for retinoid and thyroid 
hormone receptors 
ND Normal chow diet 
NF-κB Nuclear Factor kappa-light-chain-enhancer of activated B cells 
NO Nitric Oxide 
Nos2 Inducible nitric oxide synthase gene 
ns No statistically significant difference 
  
  
ABBREVIATIONS 
32 
 
O  
OPLS-DA Orthogonal partial least squares discriminant analysis 
 
P  
PBS Phosphate-buffered saline 
PCA Principal components analysis 
PCNA Proliferating cell nuclear antigen 
PCR Polymerase chain reaction 
PHx Partial hepatectomy 
Plin Perilipin gene 
PMSF Phenylmethylsulfonyl fluoride  
PPAR Peroxisome proliferator-activated receptor 
PPARα Peroxisome proliferator-activated receptor α 
PPARβ/δ Peroxisome proliferator-activated receptor β/δ 
PPARγ Peroxisome proliferator-activated receptor γ 
PPREs Peroxisome proliferator response elements 
 
Q  
QC Quality control 
qRT-PCR Quantitative real time polymerase chain reaction 
QTOF Quadrupole time of flight 
 
R  
RAF Rapidly accelerated fibrosarcoma 
RAS Rat sarcoma protein 
Rasal2 Ras GTPase activating protein-like 2 gene 
RI Retention index 
RIP1 Receptor interacting protein1 
ABBREVIATIONS 
33 
 
RNA Ribonucleic acid 
RNA-seq RNA sequencing 
ROS Reactive oxygen species 
RT Retention time 
RTL Retention time locked 
 
S  
SAPK Stress-activated protein kinases 
Scd1 Stearoyl-CoA desaturase 1 gene 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM Standard error of the mean 
Serpine1 Serpin peptidase inhibitor clade E gene 
SRC1 Steroid receptor co-activator 1 
SREBP1 Sterol regulatory element-binding protein 1 
STAT3 Signal Transducer and Activator of Transcription 3 
 
T  
T-BARS Thiobarbituric acid reactive substances 
TICs Total ion chromatograms 
TMCS Trimethylsilyl chloride 
Tnfa TNFα gene 
Tnfsf10 Tumor necrosis factor super family 10 
TNFα Tumor necrosis factor alpha 
TRAIL TNF-related apoptosis-inducing ligand 
Tris Tris(hydroxymethyl)aminomethane 
Trp53 p53 gene 
  
  
ABBREVIATIONS 
34 
 
U  
UHPLC Ultra-high performance liquid chromatography 
 
V  
VEGF Vascular Endothelial Growth Factor 
VIP Variance importance in projection values 
Vlcad Very long-chain acyl-CoA dehydrogenase 
 
W  
WAT White adipose tissue 
WHO World Health Organization 
WT Wild type 
  
  
 
  
  
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION 
  
 
INTRODUCTION 
39 
 
World Health Organization (WHO) defines cancer as the uncontrolled growth 
and spread of cells that can affect almost any part of the body. One major 
feature of cancer is the rapid insurgence of abnormal cells that grow beyond 
their usual boundaries, with the capability to invade adjoining parts of the body 
and spread to other organs. Cancer is one of the most important leading causes 
for morbidity and mortality worldwide with approximately 14 million new cases 
and 8.2 million cancer related deaths in 2012 (Figure I1). Moreover, the number 
of new cases is expected to rise about 70% in the next two decades (data from 
World Cancer Report 2014). These data remark the urgency to understand in-
depth cancer development and find new therapies.  
 
Figure I1. Cancer Incidence Age-Standardized Rate in both sexes.  
Data source: GLOBOCAN 2012, Map production: IARC, World Health Organization.  
 
1. INFLAMMATION AND CANCER 
Research along the last two decades elucidated the link between chronic 
inflammation and cancer. In fact, inflammation plays a pivotal role across all 
stages of cancer: initiation, promotion and progression. Tumor initiation requires 
the accumulation of DNA mutations (Hanahan and Weinberg, 2011). During 
chronic inflammation, activated inflammatory cells produce cytokines, such as 
tumor necrosis factor α (TNFα), which in turn induce reactive oxygen species 
(ROS) production and accumulation in target cells (Corda et al., 2001, Meier et 
al., 1989). Moreover, inflammatory cells can produce peroxynitrate (ONOO-) 
and nitrate (NO) that diffuse cell membrane and act on neighboring epithelial 
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cells (Hussain et al., 2003). Free radicals induce DNA damage as well as 
protein structural and functional modification, both being a driving factor in cell 
malignant transformation (Hussain et al., 2003). Inflammation is triggered by 
different kind of injuries, in order to eliminate the cause of damage; furthermore, 
inflammation also stimulates tissue regeneration by promoting the secretion of 
cytokines and growth factors. Those molecules can also induce tumor 
progression, as they stimulate proliferation or cell survival as a secondary effect 
(Grivennikov et al., 2010). For example, interleukin 6 (IL-6), a well-known pro-
inflammatory cytokine, induces activation of the pro-survival signaling pathway 
JAK/STAT3 (Catlett-Falcone et al., 1999, Bollrath et al., 2009, Grivennikov et 
al., 2009, Zhong et al., 1994). Moreover, activated inflammatory cells produce 
factors that stimulate neoangiogenesis, such as vascular endothelial growth 
factor (VEGF). Sustained angiogenesis is a hallmark of tumors, fundamental in 
tumor progression; blood nutrients are in fact required to sustain the high 
proliferative rate of malignant cells (Hanahan and Weinberg, 2011). Finally, 
inflammation plays a role in tumor invasion. Cancer cells invasion requires 
extracellular matrix proteolysis. Inflammatory cells are the main source of 
proteases and metalloproteinases, thus supporting tumor invasion and 
metastasis (Kessenbrock et al., 2010).  
1.1 Obesity, metabolic syndrome and cancer 
Several inflammation-inducing stimuli, such as virus infection or chronic 
exposure to irritants, can prompt cancer development through the activation of 
the immune system. In particular, evidences supporting a link between obesity, 
inflammation and cancer have been collected during the last decade. Obesity is 
considered a new global pandemic, being the most common metabolic disorder 
worldwide (WHO). Obesity, clinically defined as a body mass index (BMI) higher 
than 30, is a major cause of morbidity and mortality and it is associated with 
increased risk of type 2 diabetes mellitus, heart disease, metabolic syndrome, 
hypertension, stroke but also different forms of cancer (Haslam and James, 
2005). Epidemiological studies indicate that being overweight or obese is 
associated with increased cancer-mortality risk of 1.5 fold in men and 1.6 fold in 
women (Calle et al., 2003). Obesity promotes cancer initiation and progression 
by different mechanisms. Adipose tissue is the most important organ for lipid 
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storage. In the obese state, adipocyte enlargement induces cellular and 
metabolic changes that can affect whole-body metabolic homeostasis. In fact, 
adipocytes expansion induces hypoxia, adipocytes cell death, lipolysis with free 
fatty acids (FFA) release from adipocytes. Moreover, cytokines and chemokines 
production in adipose tissue is also increased (Sun et al., 2011). All these 
events are potent inducers of macrophages recruitment. Macrophages that are 
activated by pro-inflammatory stimuli and that express typical inflammation 
markers, such as IL-6, TNFα, NO production, are called classically activated or 
M1 macrophages. In contrast, alternatively activated or M2 macrophages 
produce anti-inflammatory cytokines, such as IL-10, and express typical anti-
inflammatory markers, such as arginase (Mantovani et al., 2004). Normal 
adipose tissue macrophages (ATM) have predominantly a M2-phenotype, while 
obesity induces a phenotypic switch in their polarization towards M1 phenotype 
(Lumeng et al., 2007). Notably, M1-infiltrated macrophages produce pro-
inflammatory cytokines, as IL-6, TNFα, IL-1β, inducing a generalized low-grade 
inflammation associated with obesity. IL-6 and TNFα are important cancer 
promoters, by inducing STAT3 and NF-κB/JNK pathways increasing cell 
survival, proliferation, angiogenesis and metastasis (Pikarsky et al., 2004, 
Zhong et al., 1994). Besides their role in lipid storage, adipocytes are important 
secretory cells; they maintain body metabolic homeostasis through adipokines 
production and secretion (Gavrilova et al., 2000). Adipose tissue remodeling 
during obesity does not involve changes in ATM phenotype only, but also in the 
adipokines profile; in fact, obesity is associated with an increase in the pro-
inflammatory cytokines production (Hotamisligil et al., 1993), a reduction in 
adiponectin circulating levels (Asayama et al., 2003), an increase in leptin 
plasma levels (Considine et al., 1996)  and a dysregulation of other adipokines 
(Antuna-Puente et al., 2008). Among all adipokines, leptin and adiponectin 
dysregulation are involved in tumor progression. Leptin is a well-studied 
adipokine that has an important role in appetite regulation. During obesity, high 
amount of circulating leptin can result in hypothalamic leptin-resistance (El-
Haschimi et al., 2000). Moreover, leptin has been described as a pro-
tumorigenic adipokine that enhances angiogenesis and induces cell survival 
through JAK/STAT3 pathway (Uddin et al., 2011). Adiponectin is one of the 
most abundant transcripts in adipose tissue (Maeda et al., 1996). It is 
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synthesized as a monomeric form that undergoes to oligomerization to form 
trimers (low molecular weight, LMW), that can associate into hexamers 
(medium molecular weight) and, finally, into multimers (high molecular weight, 
HMW) before secretion (Wang et al., 2006b). Adiponectin circulating levels are 
reduced in obesity and malignancies (Arita et al., 1999, Kelesidis et al., 2006). 
In fact, it acts as an anti-tumor molecule, by activating AMP-activated protein 
kinase (AMPK), inhibiting mTOR signaling pathway along with other pro-
tumorigenic signaling pathways, such as NF-κB/STAT3, and by enhancing p21 
and p53 activity (Dalamaga et al., 2012). Adipose tissue remodeling has an 
effect on other tissues. For example, increased-lipid efflux from adipose tissue 
is absorbed by other organs, in particular liver, pancreas and muscle. Excess of 
circulating FFA and TNFα induces insulin resistance through the inhibitory 
phosphorylation of insulin receptor substrate 1 and 2 in Serine and Threonine 
(IRS1 and IRS2) (Aguirre et al., 2002, Solinas et al., 2006, Hirosumi et al., 
2002). Insulin resistance increases circulating levels of glucose and insulin. 
Notably, hyperinsulinemia and hyperglycemia are two important tumor 
promoters: on one hand, glucose can facilitate cancer cells metabolic switch to 
glycolysis -a mechanism known as Warburg effect (Warburg, 1956)- and can 
increase cell survival under hypoxic conditions, through the induction of Hif1α 
expression (Catrina et al., 2004). On the other hand, insulin is an important 
growth factor and hyperinsulinemia per se can promote transformed cells 
proliferation (Hill and Milner, 1985). 
2. LIVER CANCER 
Liver cellularity includes two major cells types: parenchymal and non-
parenchymal cells. Parenchymal hepatocytes comprise about 80% of liver 
volume. Non-parenchymal cells include the sinusoidal endothelial cells, Kupffer 
cells, bile duct cells, hepatic stellate cells and oval cells. The most common 
primary liver cancer is hepatocellular carcinoma (HCC), which accounts for 85-
90% of liver cancers (El-Serag and Rudolph, 2007). HCC is generated by 
hepatocytes uncontrolled proliferation. Other types of liver cancers are 
cholangiocarcinoma, which originates from hyperproliferation of bile duct cells, 
and a rare malignancy named angiosarcoma, whose etiology is the proliferation 
of endothelial cells.  
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2.1 Hepatocellular carcinoma 
Hepatocellular carcinoma (HCC) is the second most common cause of death for 
cancer worldwide. Recent data estimate that HCC has been responsible for 
nearly 746,000 deaths in 2012 (9.1% of total deaths) (GLOBOCAN 2012). 
Patients diagnosed with HCC have poor prognosis and overall ratio of mortality 
to incidence is 0.95 (GLOBOCAN 2012). In fact the geographical pattern of 
incidence and mortality of HCC are quiet similar (Figure I2A and I2B). Typically, 
HCC is asymptomatic at an early stage, resulting in frequent late diagnosis. 
Together with lack of effective therapies, advance-stage disease at diagnosis 
explains the high mortality ratio observed in HCC patients (Stotz et al., 2015). In 
fact, the gold-standard therapy is considered liver transplant or partial 
hepatectomy; however, only a minority of patients is eligible for surgery due to 
the late-stage of the pathology at diagnosis (Llovet et al., 2003). 
 
Figure I2. Liver Cancer Incidence  and Mortality. 
Liver cancer Incidence (A) and mortality (B). Age Standardized Rates (ASR). Data source: 
GLOBOCAN 2012, Map production: IARC, World Health Organization.  
 
The majority of patients are treated with Sorafenib, a multi-kinase inhibitor 
targeting tyrosine kinase receptors (e.g. vascular endothelial growth factor 
receptors and platelet-derived growth factor receptor-beta) and downstream 
intracellular serine/threonine kinases (e.g. Raf-1, wild-type B-Raf and mutant B-
Raf). All these kinases control cell proliferation and tumor angiogenesis 
(Keating and Santoro, 2009). Sorafenib has several secondary effects 
(diarrhea, hand-foot skin reaction, weight loss) and can increase the overall 
survival only about 3 months (Llovet et al., 2008). Therefore, there is an evident 
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and urgent need to understand the molecular mechanism underlying HCC, in 
order to develop more specific and effective therapies. 
2.2 Obesity, inflammation and HCC 
Several malignant stimuli have been demonstrated to act as driving forces in 
HCC development (HBV and HCV infection, alcohol, aflatoxin B). Among them 
hepatitis B and C virus infection account for more than 50% of all cases of HCC 
(El-Serag, 2011). HBV or HCV infection leads to chronic liver inflammation that 
can degenerate in fibrosis, cirrhosis and, ultimately, HCC development 
(Freeman et al., 2001, Yang et al., 2011). However, several studies conducted 
in Western countries showed that 30-40% of patients with HCC does not 
present HBV or HCV infection, which indicates the presence of other drivers in 
HCC development (El-Serag, 2011). Epidemiological studies have highlighted a 
strong relation between obesity and HCC; in fact, increased BMI rises the 
relative risk of death by HCC of 4.52 and 1.68, in men and women respectively 
(Calle et al., 2003) (Figure I3).  
 
Figure I3. Mortality from 
Cancer According to 
Body-Mass Index for U.S. 
Men and Women in the 
Cancer Prevention Study 
II, 1982 through 1998. 
A) Men and B) Women 
graphical representation of 
cancer risk. For each 
relative risk the comparison 
was between subjects in the 
highest BMI category (in 
parentheses) and subjects in 
the reference category 
(BMI 18.5 to 24.9). 
Asterisks indicate relative 
risks for subjects who 
never smoked. Results of 
the linear test for trend 
were significant (p≤0.05) 
for all cancer sites. Adapted 
from Calle et al., 2003. 
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Non-alcoholic fatty liver disease (NAFLD), the liver manifestation of obesity and 
type 2 diabetes (Abdelmalek and Diehl, 2007), can degenerate in the more 
severe non-alcoholic steatohepatitis (NASH) and cirrhosis, which is the major 
risk factor for HCC development (Starley et al., 2010) (Figure I4). 
 
 
Figure I4. Progression from Healthy Liver to Hepatocellular Carcinoma. 
Different stimuli, such as FFA, pro-inflammatory cytokines, insulin or glucose excess, induce 
non-alcoholic fatty liver disease (NAFLD). This can degenerate in the more severe non-
alcoholic steatohepatitis (NASH) and cirrhosis, which is irreversible and is considered one of 
the main predisposing factors for hepatocellular carcinoma (HCC) development.  
 
The mechanistic model of HCC insurgence consists in a severe hepatocellular 
damage that induces massive hepatocytes cell death and consequent 
compensatory proliferation. Sustained cycles of hepatocytes destruction-
compensatory proliferation lead to accumulation of mutations in proliferative 
hepatocytes (Baffy et al., 2012, Fujimoto et al., 2016). Several mechanisms of 
hepatocellular damage take place during obesity and other associated 
metabolic disorders. The most remarkable feature of NAFLD is FFA 
accumulation in hepatocytes that leads to hepatic lipotoxicity. Excess of 
nutrients activates mammalian target of rapamycin complex 1 (mTORC1), 
which in turn, stimulates lipogenesis through the induction of the sterol 
regulatory element-binding protein 1 (SREBP1) (Han et al., 2015), enhancing 
lipid accumulation. Moreover, mTORC1 activation inhibits cell autophagy (Kim 
et al., 2011). Hypernutrition also inhibits AMPK activation, an important inducer 
of autophagy (Kim et al., 2011). Reduced autophagy results in aberrant proteins 
and mitochondria accumulation, which increase endoplasmic reticulum (ER) 
stress and ROS production, respectively (Wang et al., 2006a, Takamura et al., 
INTRODUCTION 
46 
 
2011), causing hepatocytes cell death. Sustained hepatocytes necrosis and 
apoptosis activate Kupffer cells, increasing IL-6 and TNFα secretion. These two 
molecules are able to activate JAK/STAT3 and NF-κB pathways, providing both 
pro-survival and anti-apoptotic stimuli to mutated hepatocytes (Park et al., 
2010), thus enhancing tumor progression. Taking together these data, a clear 
link between obesity induced-NAFLD and HCC emerges. However, further 
investigation on the role of metabolic genes in HCC development is needed, in 
order to elucidate the mechanisms underlying such correlation. 
3. METABOLIC GENES 
3.1 Stress-activated protein kinases 
Mitogen-activated protein kinases (MAPK) is a family of protein kinases that 
transduce a variety of extracellular signals, regulating cellular responses (Sabio 
and Davis, 2014). Three groups of MAPKs have been identified: the epithelial 
signal-regulated kinases (ERKs), the p38 MAPKs, and the c-Jun N-terminal 
kinases (JNKs). While ERKs are mainly activated by mitogens and 
differentiation signals, JNKs and p38 MAPKs are activated by stress stimuli and 
are collectively known as stress-activated protein kinases (SAPKs) (Manieri and 
Sabio, 2015). The SAPK family is composed of the four isoforms of p38 (p38α, 
β, γ, δ) and the three isoforms of JNK (JNK1, 2, and 3) (Paul et al., 1997).  
3.1.1 c-Jun N-terminal kinases 
JNKs isoforms are encoded by three genes, located in different chromosomes 
and conserved among species: Jnk1 and Jnk2 are ubiquitously expressed, 
while Jnk3 is specifically expressed in brain, testis and heart (Davis, 2000, 
Chang and Karin, 2001). Several splice variants have been described for each 
JNK member, and they can be separated in two groups based on their size: the 
short forms of about 46 kDa (JNK1a1, JNK1b1, JNK2a1 JNK2b1 JNK3a1) and 
the long forms of about 54 kDa (JNK1a2, JNK1b2, JNK2a2 JNK2b2 JNK3a2) 
(Gupta et al., 1996). JNK1 short isoforms predominate over JNK2 short variants 
in the majority of cell types, while the reverse pattern is observed for the long 
forms (Gupta et al., 1996). The function and the exact modulation of each of 
these splice variants is still unsolved. A wide range of stimuli induces JNKs 
activation, such as environmental stresses (hypoxia, U.V., ionizing radiation), 
toxins, drugs, TNFα and IL-6 and metabolic changes, including hyperlipidemia. 
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These stimuli induce a phosphorylation cascade that culminates with the 
activation of JNKs, which induces the proper response to a specific stimulus, 
characterized by apoptosis, cell proliferation, differentiation or cell migration. 
JNKs activation is mediated by a dual phosphorylation on tyrosine and 
threonine in the conserved Thr-Pro-Tyr motif in their activation loop. Two MAP 
kinase kinases, MKK4 and MKK7 mediate such phosphorylation events (Paul et 
al., 1997). More than fifty proteins have been identified as JNKs substrates. 
These include c-Jun, which once phosphorylated can dimerize with JunB, JunD 
or c-Fos to form the transcription factor activator protein-1 (AP-1) (Hotamisligil 
et al., 1996). Other important substrates are insulin receptor substrate 1 (IRS1) 
(Lee et al., 2003); c-MYC; p53, and numerous transcription factors (Davis, 
2000, Chang and Karin, 2001).  
 
Figure I5. Schematic representation of JNKs pathways. 
Cellular stress stimuli, such as cytokines, FFA and U.V., activate a phosphorylation cascade, 
which culminates with JNKs activation. JNKs phosphorylate their substrates inducing a 
stimulus-specific cell response. 
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3.1.2 JNKs in HCC 
JNKs play a central role in cell response to stress stimuli, and they are able to 
induce apoptosis or cell proliferation depending on the stimulus nature and of its 
intensity. For this reason, their role has been studied in tumor development, 
highlighting isoform-specific, cell-specific and tumor-specific influence of JNK 
family members in cancer (Wagner and Nebreda, 2009). In addition, 
sequencing analyses of human cancer specimens have identified somatic 
mutations at JNK1 and JNK2 and upstream kinase MKK7, suggesting their 
importance in tumor development (Greenman et al., 2007, Jones et al., 2008). 
C-Jun, a downstream effector of JNKs pathway, has been shown to have a 
promoting function through suppression of p53 pathway in liver cancer (Eferl et 
al., 2003). Moreover, JNK1 activation is increased in p38α knock out 
hepatocytes, promoting tumorigenesis (Hui et al., 2007). JNK1, but not JNK2, 
constitutive knock out mice are protected against chemical-induced HCC 
development, due to p21 up-regulation and c-MYC down-regulation (Hui et al., 
2008). Furthermore, it has been described a differential role for JNK1 and JNK2 
in hepatocytes and liver non-parenchymal cells (Das et al., 2011). Das and 
colleagues demonstrated that deficiency of JNK1 and JNK2, specifically in 
hepatocytes, enhance tumor growth. In contrast, their depletion in both 
hepatocytes and non-parenchymal cells strongly suppress tumor growth (Das et 
al., 2011). They observed p21 up-regulation in both systems, but c-MYC 
downregulation only in the latter one, indicating a potential role for JNK in c-
MYC expression during HCC development. Compensatory proliferation plays a 
major role in HCC development (Grivennikov et al., 2010), and it could be 
stimulated by cytokines produced by hepatic immune cells (Naugler et al., 2007, 
Park et al., 2010). Das and colleagues demonstrated a reduction in cytokines 
production in the context of JNK depletion in both, parenchymal and non-
parenchymal cells, followed by a reduction in cell death and compensatory 
proliferation (Das et al., 2011). Together these results support a pro-
inflammatory and pro-tumorigenic role of JNK1 and 2 in non-parenchymal cells, 
causing cytokines expression and compensatory proliferation, while 
hepatocytes JNKs expression appears to decrease cell death and 
compensatory proliferation during HCC (Das et al., 2011).  
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3.1.3 JNK in metabolism 
A part from their role in tumor development, JNK-SAPK family has a major role 
in obesity and metabolic disorders. In fact, JNK3 has been recently described 
as a key player in regulating feeding behavior under HFD stimulus (Vernia et 
al., 2016), while a large body of literature indicates JNK1 and JNK2 isoforms as 
important regulators of obesity-induced inflammation and metabolic disorders 
(Tuncman et al., 2006, Singh et al., 2009, Han et al., 2013). JNK pathway is 
strongly activated in liver, adipose tissue and muscle during dietary and 
genetically induced obesity, and mice knockout for JNK1, but not JNK2, are 
protected against obesity and insulin resistance (Hirosumi et al., 2002). For this 
reason the majority of research carried out on JNKs and metabolic disorders is 
especially focused on JNK1 and its tissue-specific role in metabolism (Sabio et 
al., 2009, Sabio et al., 2008, Solinas et al., 2007, Sabio et al., 2010). These 
studies took advantage of JNK1 tissue-specific knock out models, and 
highlighted a double influence of JNK1 in metabolism: on the one hand, JNK1 
induces a cell-autonomous effect, influencing the response of the cell to obesity; 
on the other hand, JNK1 influences the crosstalk between different organs, 
modifying their response to obesity-associated effects. Of particular interest for 
this Thesis is the role that JNK1 exerts in adipose tissue. JNK1 deletion in 
adipocytes does not influence HFD-induced weight gain, but protects adipose 
tissue against obesity-induced insulin resistance. Moreover in absence of JNK1, 
adipose tissue IL-6 production is reduced, protecting liver from steatosis and 
insulin resistance development (Sabio et al., 2008). As mentioned before, liver 
steatosis can degenerate in NAFLD and the more severe NASH, which are 
predisposing factors for HCC development (Starley et al., 2010). Despite the 
pivotal role played by JNK1 in inflammation, metabolism and HCC, its 
involvement in organs crosstalk and liver carcinogenesis has not been well 
studied. 
3.2 Peroxisome proliferator-activated receptors 
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated 
receptors that belong to the nuclear hormone receptor superfamily. In mammals 
there are three PPAR isoforms: PPARα (encoded by Nr1c1 gene), PPARβ/δ 
(Nr1c2) and PPARγ (Nr1c3) (Issemann and Green, 1990, Kliewer et al., 1994). 
Each isoform is encoded by a different gene and has a tissue-specific 
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expression depending of their functions. Expression of PPARα is highest in 
tissues with high levels of β-oxidation, as liver, brown adipose tissue, hearth, 
kidney and immune cells (Mandard et al., 2004); PPARγ is mainly expressed in 
adipose tissue and intestine, (Fajas et al., 1997), whereas PPARβ/δ is 
ubiquitously expressed (Girroir et al., 2008). PPARs are lipid sensors, and they 
are activated by dietary fatty acids and their metabolic derivatives. PPARs are 
present in the nucleus associated with retinoid X receptors (RXRs) and the 
nuclear receptor co-repressor/silencing mediator for retinoid and thyroid 
hormone receptors (NCoR/SMRT). PPARδ is the only isoform that can bind to 
DNA while is associated with NCoR/SMRT co-repressor. After ligand binding, 
PPARs can move apart from the co-repressor and bind to DNA sequences 
named peroxisome proliferation response elements (PPREs) in the promoter of 
their target genes and to co-activator complexes such as steroid receptor co-
activator 1 (SRC1) and cAMP response element binding (CREB)-binding 
protein (CBP/p300) (Daynes and Jones, 2002). PPREs contain repeats of the 
sequence AGGTCA separated by one or two nucleotides (named DR1 and DR2 
respectively) and are located in the promoter region of target genes (Tugwood 
et al., 1992, Mascaro et al., 1999, Green and Wahli, 1994, A et al., 1997). Each 
PPAR isoform responds to different types of ligands, exerting a different 
function (Kliewer et al., 1994).  
3.2.1 PPARα 
PPARα is highly expressed in liver and it is a major regulator of hepatic lipid 
metabolism. Endogenous ligand of PPARα include fatty acids (FA), in particular 
omega-3 fatty acids, such as arachidonic acid, linoleic acid, docosahexaenoic 
acid, eicosapentaenoic acid, eicosanoids derivatives as leukotriene B4 (Krey et 
al., 1997); synthetic ligands include principally fibrates and pirinix acid 
(WY14,643) (Briguglio et al., 2010). Ligand binding induces expression of genes 
involved in lipid metabolism, in particular fatty acid oxidation, ketogenesis, lipid 
transport and gluconeogenesis (Pawlak et al., 2015). In addition to its role in 
metabolism, PPARα exerts also an anti-inflammatory function (Devchand et al., 
1996, Staels et al., 1998). 
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Figure I6. Schematic representation of PPARs activation. 
Free fatty acids (FFA) and their derivatives are internalized by FFA receptor. They are 
recognized by cytosolic L-FABP, which brings them to the inhibited complex RXR-PPAR-
NCoR/SMRT. Ligand binding induces co-repressor NCoR/SMRT separation from the complex 
and RXR-PPAR. After dissociation from co-repressor, RXR-PPAR complex can bind to PPRE 
DNA sequences. PPARs can bind co-activator complexes, such as SRC1 and CBP/p300, 
activating gene transcription. 
 
3.2.2 PPARα in metabolism 
Fatty acids (FA) are transported in the cell by membrane-associated fatty acid 
transport proteins (FABPs) (Schaffer and Lodish, 1994). Genes encoding for 
some FABPs are direct targets of PPARα, indicating that activation of PPARα 
enhances FA entrance in the cell (Martin et al., 1997). Among them L-Fabp 
gene have been described to present PPREs sequence and protein binding 
between PPARα and L-FABP has been reported, suggesting that L-FABP may 
channel PPARα ligands to the receptor (Helledie et al., 2002). A part from 
genes controlling FA trafficking, PPARα is an important transcription factor for 
rate-limiting enzymes of peroxisomal β-oxidation, as Acox1 (Peroxisomal Acyl-
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CoA Oxidase 1) and Ehhadh (Peroxisomal bifunctional enzyme) (Dreyer et al., 
1992); Cpt-I and Cpt-II that trigger FA transport through mitochondria 
membrane (Mascaro et al., 1998); and medium, long and very long-chain acyl-
CoA dehydrogenase genes (Mcad, Lcad, Vlcad) (Gulick et al., 1994, Aoyama et 
al., 1998). Moreover, hepatic PPARα activity is enhanced in fasting conditions, 
because of the increase in fatty acids oxidation due to ketogenesis. In this 
context, PPARα induces expression of genes involved in ketogenesis and fatty 
acid oxidation, in particular Fgf21 that is a key mediator of these processes 
(Badman et al., 2007). In addition PPARα induces lipoprotein lipase (LPL) gene 
expression and inhibits mRNA production of a LPL inhibitor (APO-CIII), 
increasing the hydrolysis of lipoprotein triglyceride in FFA (Schoonjans et al., 
1996a, Hertz et al., 1995). Finally PPARα controls hepatic lipogenesis 
enhancing Srebp1c transcription in humans and SREBP1c target genes in mice 
(Fas, Acc1 and Scd-1) (Fernandez-Alvarez et al., 2011, Patel et al., 2001). 
Taking into account all the functions of PPARα in controlling hepatic 
metabolism, it is clear its role as a sensor and regulator of liver energy balance. 
3.2.3 PPARα in inflammation 
Beyond its fundamental role in hepatic metabolism, PPARα has a prominent 
role in inflammation. Using Ppara-/- mouse model and fibrates, different groups 
showed its role as anti-inflammatory protein. In fact, Ppara-/- mice suffered 
prolonged inflammatory response when treated with leukotriene B4 (LTB4) in 
the ear-swelling test (Devchand et al., 1996). LTB4 is a pro-inflammatory 
eicosanoid that binds PPARα inducing the transcription of ω and β-oxidation 
genes, which lead to its catabolism (Devchand et al., 1996). In addition, 
splenocytes from Ppara-/- mice respond to lipopolysaccharide (LPS) stimulation 
producing two to three times more pro-inflammatory cytokines as IL-6 and IL-12 
than WT cells (Poynter and Daynes, 1998). Furthermore, PPARα ligands inhibit 
IL-1-induced IL-6 production and cyclooxygenase-2 expression in smooth-
muscle cells (Staels et al., 1998). PPARα also acts through the repression of 
NF-κB signaling to reduce prostaglandin production (Staels et al., 1998). These 
data underlie a protective role of PPARα against inflammation. 
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3.2.4 PPARα and HCC development 
PPARα has a pivotal role in protect liver from steatosis and obesity-induced 
hepatic inflammation (Stienstra et al., 2007, Ip et al., 2003) and use of PPARα 
agonists, as fibrates, seem to have a promising activity contrasting obesity 
effects (Forman et al., 1997, Schoonjans et al., 1996b). However, its role in 
hepatocellular carcinoma development is less clear. It has been shown that 
mice lacking PPARα are more prone to chemical-induced HCC development, 
due to increased activation of NF-κB pathway and consequent escape from 
apoptosis (Zhang et al., 2014). In addition, in vitro studies on HCC cell lines 
demonstrate growth inhibitory effect of PPARα agonists (Panigrahy et al., 2008, 
Maggiora et al., 2010). Conversely, studies with PPARα agonists as Wy14-643 
showed increase HCC development in WT mice, due to increased DNA in 
synthesis, while Wy14-643-treated Ppara-/- mice were refractory to HCC, 
suggesting a PPARα promoting effect (Peters et al., 1997). Moreover, PPARα 
activation has been described to be essential in the HCV-induced liver steatosis 
and HCC development (Tanaka et al., 2008). Tanaka and colleagues 
demonstrated that Ppara-/- mice expressing HCV core protein are protected 
against HCC development, while increasing activation of PPARα in 
heterozygous mice with clofibrate enhances liver tumorigenesis (Tanaka et al., 
2008).  
Concluding, PPARα has a fundamental role in hepatic metabolism and 
inflammation. Thus, elucidate its function in HCC development in physiological 
conditions that enhance its activation, as obese state, would be helpful to find 
new therapies for this malignancy.  
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Hepatocellular carcinoma is the second cause of cancer-related death. 
Epidemiological studies suggest an association of liver cancer with obesity and 
metabolic disorders. However the mechanisms underlying this correlation and 
the link between adipose tissue and liver cancer are poorly understood. The aim 
of this Thesis is to study two metabolic genes, JNK1 and PPARα, to understand 
how their function as metabolic controllers could affect hepatocellular carcinoma 
development. 
1. Study the role of adipose tissue JNK1 in hepatocellular carcinoma 
development 
1.1 Evaluate the effect of adipose tissue JNK1 on chemical-induced liver 
tumorigenesis in normal chow diet and high fat diet conditions 
1.2 Analyze the consequences of JNK1 ablation in adipose tissue 
1.3 Unveil the molecular mechanism through which adiponectin inhibits hepatic 
tumorigenesis 
1.4 Identify other possible target of JNK1 that can have a role in adipose tissue 
to liver crosstalk during hepatocellular carcinoma development 
2. Elucidate the role of PPARα in liver cancer development during obesity 
2.1 Study the effect of PPARα on chemical-induced liver tumorigenesis in 
normal chow diet and high fat diet conditions 
2.2 Define in which cellular compartment PPARα is important for liver 
tumorigenesis 
2.3 Elucidate the molecular mechanism through which PPARα controls this 
process 
2.4 Verify the importance of PPARα in liver cancer using another model to 
induce its activation 
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1. ROLE OF JNK1 IN ADIPOSE TISSUE-LIVER CROSSTALK IN HCC 
DEVELOPMENT 
Animals 
Experimental model was generated as previously described (Sabio et al., 2008). 
Briefly, mice in which JNK1 gene was flanked by LoxP sequences (Jnk1f/f) 
(generated in Roger J. Davis’ laboratory) were crossed with mice expressing 
Cre recombinase under the control of adipose tissue specific Fabp4 promoter 
(Fabp4-Cre) (He et al., 2003). To reduce the LoxP sequence recombination and 
achieve a better depletion of Jnk1 gene, we crossed these mice with full knock 
out Jnk1 mice (Jackson Laboratories; B6.129S1-Mapk8 tm1Flv/J, here called 
Jnk1-/-), obtaining Fabp4-Cre+Jnk1f/- mice (FKO mice).  Littermates without 
conditional Jnk1 allele (Fabp4-Cre+Jnk1+/-) were used as control mice (FWT) 
(Figure M1). 
 
 
Figure M1. Schematic representation of mouse lines crossing to generate F
WT
 and F
KO 
mice. 
Fabp4-Cre
+
 mice were crossed with Jnk1
f/f
 to obtain Fabp4-Cre
+
Jnk1
f/+
 mice. These mice were 
crossed with Jnk1
-/-
 mice generating Fabp4-Cre
+
Jnk1
+/-
 (F
WT
) and adipose tissue JNK1 specific 
knock out Fabp4-Cre
+
Jnk1
f/-
 (F
KO
) mice.  
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Adiponectin knock out mice were purchased from Jackson Laboratories 
(B6;129-Adipoq tm1Chan/J, here called Adipoq -/-). These mice were 
crossed with Fabp4-Cre+Jnk1f/f mice and Jnk1-/- mice as represented in Figure 
M2, to generate FKOAdipoq-/- and FWTAdipoq-/- models (Figure M2).  
 
Figure M2. Schematic representation of mouse lines crossing to generate F
WT
Adipoq
-/-
 and 
F
KO
 Adipoq
-/-
 mice. 
Representation of mouse lines crossing to generate control F
WT
Adipoq
-/-
 and adipose tissue 
JNK1 specific knock out F
KO
Adipoq
-/-
 mice. On one side Fabp4-Cre
+
Jnk
f/f
 mice were crossed 
with adiponectin knock out (Adipoq
-/-
) mice to obtain Fabp4-Cre
+
Jnk1
f/+
Adipoq
-/-
 mice. On the 
other side Jnk1
-/-
 mice were crossed with Adipoq
-/-
 to obtain Jnk1
-/-
Adipoq
-/-
 mice. Finally, 
Fabp4-Cre
+
Jnk1
f/+
Adipoq
-/-
 mice were crossed with Jnk1
-/-
Adipoq
-/-
 mice to obtain Fabp4-
Cre
+
Jnk1
+/-
Adipoq
-/-
 (F
WT
Adipoq
-/-
) and Fabp4-Cre
+
Jnk1
f/-
Adipoq
-/-
  (F
KO
 Adipoq
-/-
) mice 
 
Genotypes were identified by PCR analysis of genomic DNA isolated from 
mouse-tails. All experiments were performed in male mice. For tumor studies, 
mice on postnatal day 14 received a single i.p. injection of 50 mg/kg body 
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weight diethylnitrosamine (DEN, Sigma-Aldrich) dissolved in saline. Six weeks 
after DEN treatment, mice were fed a high-fat diet (HFD, Research Diet Inc.) or 
standard chow diet ad libitum until sacrifice 8 months after DEN injection. 
Tumors were measured with an analogical caliber. Before sacrifice, body weight 
was measured and blood samples were taken for metabolomics and cytokines 
analysis. For time course studies mice were sacrificed 15 days and 1 month 
after DEN injection. In all cases, mice were euthanized after overnight 
starvation.  
For partial hepatectomy (PHx) experiments adult mice (8-12-week-old), were 
anesthetized using a mixture of isoflurane and oxygen. Two-thirds of the liver 
was excised according to Mitchell and Willenbring (Mitchell and Willenbring, 
2008), medial and left lateral lobes were removed. Mice were sacrificed 48 
hours or 15 days after PHx and their liver was weighted to analyze hepatic 
mass regeneration. 
Mice were housed in a pathogen-free animal facility and kept on a 12-hour 
light/dark cycle at constant temperature and humidity. All animal experiments 
conformed to EU Directive 2010/63EU and Recommendation 2007/526/EC, 
enforced in Spanish law under Real Decreto 53/2013 
Cell culture 
Hep53.4 cell line was purchased from CLS-Cell Lines Service GmbH. It is an 
established cell line generated from DEN-induced HCC in C57BL/6J mice as 
previously described (Kress et al., 1992). Hep53.4 cells were cultured in DMEM 
supplemented with 10% FBS, L-glutamine and penicillin/streptomycin.  
Retrovirus production 
Retrovirus expressing p38α D176A/F327S was produced in HEK-293 Phoenix-
ECO cell line, which is stably transfected to express Moloney Murine Leukemia 
Virus (M-MLV) viral packaging proteins. Transient calcium phosphate co-
transfection of HEK-293 Phoenix-ECO cells was done with 20 µg of 
pBABE.p38αD176A/F327S (courtesy of Dr. Ángel Nebreda’s laboratory) or 
pBABE EMPTY VECTOR together with 2.5 µg of packaging virus DNA. The 
supernatants containing the retrovirus particles were collected 48 and 72 hours 
after removal of the calcium phosphate precipitate and were filtered with 0.45 
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µm filter. Virus has been concentrated by ultracentrifugation for 90 minutes 
49,000 x g at 4 °C (Ultraclear Tubes, Beckman Coulter; Optima XPN-100 
Ultracentrifuge Beckman, SW28 rotor).  
Xenograft 
For xenograft experiments 5 x 104 Hep53.4 cells were mixed 1:1 with Corning® 
Matrigel® Matrix (Corning) and subcutaneously injected in each flank of 
anesthetized mice. Tumor growth was monitored measuring length and width 
every 3-4 days with a digital caliber. At final point mice were sacrificed and 
tumors were extracted. Length, width and thickness were measured to 
established tumor volume.  
In AMPKα activation by metformin experiment mice were treated with metformin 
dissolved in drinking water (300 mg/day/Kg) starting one week before xenograft 
injection and changing water every day. Mice body weight was measured every 
week. 
Metabolomics 
Metabolomics analysis was carried out by the Advanced Imaging Unit at CNIC. 
Serum samples from FWT and FKO mice 8 months after DEN-treatment were 
analyzed. 
Metabolite extraction and derivatization.  
Plasma samples were prepared for gas chromatography-mass spectrometry 
(GC−MS) analysis as previously described (Garcia and Barbas, 2011). Proteins 
were precipitated with acetonitrile and separated by centrifugation (15,400 x g). 
After deproteinization step supernatant was transferred to another glass vial 
and then evaporated to dryness in a Speedvac Concentrator (Thermo Fisher 
Scientific, Waltham, MA, USA). Derivatization was achieved in different stages: 
O-methoxyamine hydrochloride in pyridine and methoxymation was carried out 
overnight. N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA) with 1% 
Trimethylsilyl chloride (TMCS) was then added, and after silylation, sample was 
dissolved in heptane with C18:0 methyl ester (IS).  
Quality Control (QC) 
For quality checking, electropherograms from serum samples and quality 
controls (QCs) were tested. QC samples were prepared by combining equal 
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volumes of serum from each sample. Five samples were independently 
prepared from this pool of samples, by following the same procedure as for the 
other samples. QC samples were analyzed throughout the run to provide a 
measure of the system’s stability, performance and reproducibility of the 
sample-treatment procedure.  
GC-MS analysis 
GC−MS analyses were performed by a 7890A gas chromatography instrument 
(Agilent Technologies, Santa Clara, CA, USA) interfaced to inert 
macromolecular structure database (MSD) with Quadrupole (Agilent 
Technologies 5975). 2 μl of previously derivatized samples was injected in split 
mode using an Agilent Technologies 7693 autosampler onto a GC column DB5-
MS (30 m length, 0.25 mm i.d., 0.25 μm film 95% dimethyl/5% 
diphenylpolysiloxane) with an integrated pre-column (10 m J&W) from Agilent 
Technologies. Carrier gas (He) flow rate was set at 1 ml/min and injector 
temperature at 250 °C. Split ratio was fixed from 1:5 to 1:10 with 3 to 10 ml/min 
He split flow into a Restek 20782 (Bellefonte, PA, USA) deactivated glass-wool 
split liner. Temperature gradient was programmed: initial oven temperature was 
set at 60 °C (held for 1 minute), then increased to 325 °C at 10 °C/min, and 
finally a cool-down period was applied for 10 minutes before the next injection. 
Total analysis time was 37.5 minutes. Detector transfer line, filament source, 
and quadrupole temperatures were set at 290 °C, 230 °C, and 150 °C, 
respectively. Serum samples from FWT and FKO mice 8 months after DEN-
treatment were analyzed by means of a metabolic fingerprinting approach using 
liquid chromatography-mass spectrometry (LC−MS) platform. To remove 
phospholipids and proteins, 225 µl of serum and 10 µl of methionine sulfone, 
internal standard (IS), were vortex-mixed with 300 µl of methanol-ammonium 
foremate (1:1, v/v) and then passed through a Supelco HybridSPE Phospholipid 
Ultra cartridge (Supelco, Sigma Aldrich). The extracts were then dried at 35 ºC 
by use of a speedvac and dissolved in 100 µl of 0.1 mol/l of formic acid. After 
centrifugation (16,000 x g, 4 ºC, 20 minutes) supernatant was transferred 
directly to a vial (Chromacol, UK) ready for injection.   
Samples were analyzed by an Ultra-high performance liquid chromatography 
(UHPLC) system (1290 Infinity series, Agilent Technologies, Waldbronn, 
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Germany) consisting of a degasser, two binary pumps, and thermostated 
autosampler connected to an Agilent Technologies QTOF (6550) mass 
spectrometry detector. Electrospray ionization (ESI) was used as an ion source. 
Samples (0.5 µl) were injected onto a reversed-phase column (Zorbax Extend 
C18, 2.1 × 5.0 mm, 1.8 μm, Agilent Technologies) thermostated at 60 °C. The 
system was operated in positive and negative mode at 0.6 ml/min flow rate with 
solvent A, water with 0.1% of formic acid, and solvent B, acetonitrile with 0.1% 
of formic acid. Gradient started from 5% of solvent B for the first minute, then to 
80% in minute 7, then to 100% in minute 11.5, and returned to starting 
conditions in 0.5 minutes, keeping the re-equilibration until minute 15.  
Data were collected in positive and negative ESI ion modes in separate runs. 
The detector operated in full scan mode from 50 to 1,000 m/z for positive mode 
and from 50 to 1,100 m/z for negative mode with a scan rate of 1 scan per 
second. Accurate mass measurements were obtained by means of an 
automated calibrant delivery system using ESI source with Jet Stream 
technology that continuously introduced a calibration solution, with reference 
masses at m/z 121.0509 (protonated purine) and m/z 922.0098 [protonated 
hexakis(1H,1H,3H- tetrafluoropropoxy)phosphazine or HP-921] in positive ion 
mode; and m/z 112.9856 (TFA anion) and m/z 1033.9881 [hexakis(1H,1H,3H-
tetrafluoropropoxy)phosphazine or HP- 0921] in negative ion mode. The 
capillary voltage was set to 3,000 V for both positive and negative ionization 
modes, and the nebulizer gas flow rate was 12 l/min. Randomized samples 
were analyzed in two separate runs (first for positive and second for negative 
mode).  
GC-MS and LC-MS data treatment and metabolite identification 
Data were acquired using the Agilent MSD ChemStation Software. Total ion 
chromatograms (TICs) were inspected according to quality of chromatograms 
and internal standard signal. Peak detection and deconvolution were 
automatically performed with Automated Mass Spectrometry Deconvolution and 
Identification System (AMDIS, www.amdis.net). Then, deconvoluted 
compounds were identified according to retention time (RT), retention index 
(RI), and mass spectrum. RI calculation relies on conversion of RT into 
constants, which are independent of system variability.  
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RI for each compound was obtained by normalization of its RT by the RT and RI 
of the closest eluting n-alkane, presented in the mix of fatty acid methyl esters, 
which was injected before the samples. Based on mass spectrum and RI 
comparison with those from the Fiehn RTL library, the list of identified 
compounds was created. Additionally, mass spectra of possible compounds, 
which have not been found in the Fiehn RTL library, were searched through the 
NIST mass spectral library. According to this information, the in-house target 
library was created with RT and target m/z data. Multialignment was performed 
by MassProfiler Professional B.02.02 software (Agilent Technologies). 
Subsequently, filtering on frequency, sum of the derivatives, and normalization 
to IS were performed before statistical analysis.  
Statistical analysis 
An unsupervised multivariate analysis, Principal components analysis (PCA), 
was applied to check trends, outliers, and the quality of the analysis. Supervised 
multivariate analysis, such as orthogonal partial least squares discriminant 
analysis (OPLS-DA), was required to select metabolites that contributed most to 
separation and discrimination between groups. Statistically significant 
metabolites were selected based on the Jack-knife confidence interval (p<0.05) 
and variable importance into projection Variance Importance in Projection 
values (VIP). Compounds detected by LC-MS were first putatively identified 
using public available databases. The identity of compounds found in the 
databases was confirmed by LC−MS/MS analyses. For GC-MS, metabolites 
found to be statistically significant were identified based on comparison of their 
retention time, retention index and mass spectra with Fiehn RTL library, in-
house target plasma library or NIST library. 
Validation of the PLS-DA model 
To avoid the risk of overfitting for a PLS-DA model used for selection of 
statistically significant metabolites according to Jack-knifed confidence intervals, 
the model was validated by use of a cross-validation tool, using one third out 
approach.  
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Histology 
Adipose tissue was fixed with 10% formalin and embedded in paraffin. Sections 
were cut (4 µm) and stained with hematoxylin and eosin (American Master Tech 
Scientific) for histopathological examination. 
Real Time qPCR 
Total RNA was isolated from liver, tumor and adipose tissues using the RNeasy 
Mini Kit (Qiagen) with on-column DNase I-digestion. Complementary DNA was 
synthesized with the High-Capacity Complementary DNA Reverse Transcription 
Kit (Applied Biosystems). Sequences of primers used for quantitative real-time-
polymerase chain reaction (qRT-PCR) are provided in Table I. Expression 
levels were normalized to Gapdh mRNA. qRT-PCR was performed using Fast 
SYBR Green system (Applied Biosystems) in a 7900HT Fast Real-time PCR 
thermal cycler (Applied Biosystems). A dissociation curve program was 
employed after each reaction to verify primers specificity.  
Luminex 
Serum cytokine concentrations were measured by multiplexed ELISA with a 
Luminex 200 analyzer (Millipore). 
Biochemical analysis 
Total proteins were extracted in lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM 
EGTA, 1 mM EDTA pH 8.0, 50 mM NaF, 1 mM sodium glycerophosphate, 5 
mM pyrophosphate, 0.27 M sucrose, 1% Triton X-100, 0.1 mM PMSF, 0.1% 2-
mercaptoethanol, 1 mM sodium-ortovanadate, 1 µg/ml leupeptin, 1 µg/ml 
aprotinin). Extracts were separated by SDS–PAGE and transferred to 0.2 µm 
pore size nitrocellulose membranes (Bio Rad). Blots were probed with primary 
antibodies to JNK (#9252); phospho AMPKα (#2531); AMPKα (#26035); FLIP 
(#3210); phospho p38α (#9211) from Cell Signaling Technology; p38α (sc-535) 
from Santa Cruz Biotechnology, Inc.; Vinculin (V4505) from Sigma-Aldrich. All 
antibodies were used at 1:1000 dilution. After washes, membranes were 
incubated with an appropriate horseradish peroxidase-conjugated secondary 
antibody (GE Healthcare), and signal was detected using an enhanced 
chemiluminescent substrate for the detection of horseradish peroxidase (Clarity 
Western ECL substrate; Biorad). Protein levels were analyzed by optical density 
with ImageJ. For adiponectin detection, plasma samples were run in native 
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conditions. Samples were diluted in PBS (1:10) and with Native Tris-Glycine 
Sample Buffer 2X (Invitrogen). Diluted samples were loaded on pre-cast native 
gels to preserve adiponectin multimers (NativePAGE™ Bis-Tris gel system, 
Thermo Fisher Scientific) and run with Novex Tris-Glycine Native Running 
Buffer (Invitrogen). After transference membrane was blocked with milk 
prepared in PBS without detergents. Blot was probed with primary antibody to 
Adiponectin (PA1-054) from Thermo Fisher Scientific, 1:500 dilution. After 
washes, membranes were incubated with a fluorescent secondary antibody 
(Goat anti rabbit 680nm 926-32221, Odyssey). Signal was detected and 
analyzed by Odyssey LI-COR.  
RNA-sequencing 
RNA-sequencing was done in collaboration with Genomics Unit, CNIC. 
Total RNA was isolated from adipose tissue using the RNeasy Mini Kit (Qiagen) 
with on-column DNase I-digestion. Samples were pooled two by two to obtain 1 
µg of total RNA (500 ng from each pooled-sample). Total RNA was processed 
with TruSeq RNA Sample Preparation to create a cDNA library from each pool. 
Libraries were sequencing with Illumina Genome Analyzer IIx Sequencing 
System. Total RNA processing with TruSeq RNA Sample Preparation and 
sequencing were performed by Genomic Unit at CNIC. 
Data obtained from RNA sequencing were analyzed using Ingenuity® Pathway 
Analysis (IPA).  
Statistical analysis 
Differences between groups were examined for statistical significance using 2-
tailed Student’s t test or ANOVA coupled to Bonferroni’s post-test. 
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TABLE I – qRT-PCR primers 
GENE Forward Primer Reverse Primer 
Plin ACAGCAGAATATGCCGCCAA GGCTGACTCCTTGTCTGGTG 
Nos2 GTTCTCAGCCCAACAATACAA GTGGACGGGTCGATGTCAC 
Tnfsf10 ATGGTGATTTGCATAGTGCTCC GCAAGCAGGGTCTGTTCAAGA 
Rasal2 ATGGAGCTGTCTCCGTCGT GCCTTTTACATCGAACACCCG 
Serpine1 TTCAGCCCTTGCTTGCCTC ACACTTTTACTCCGAAGTCGGT 
Lyz2 ATGGAATGGCTGGCTACTATGG ACCAGTATCGGCTATTGATCTGA 
Emr1 CCCCAGTGTCCTTACAGAGTG GTGCCCAGAGTGGATGTCT 
Il6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
Il1b GCAACTGTTCCTGAATCAACT ATCTTTTGGGGTCCGTCAACT 
Tnfa CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG 
Gapdh TGAAGCAGGCATCTGAGGG CGAAGGTGGAAGAGTGGGA 
 
  
MATERIALS AND METHODS 
2. ROLE OF PPARα ACTIVATION IN LIVER CANCER 
71 
 
2. ROLE OF PPARα ACTIVATION IN LIVER CANCER 
Animals  
PPAR knock out mice (B6;129S4-Pparatm1Gonz/J, here called Ppara-/-) and 
Albumin Cre-recombinase mice (B6.Cg-Tg(Alb-cre)21Mgn/J, here called LWT) 
were purchased from Jackson Laboratory. Mice with compound JNK1/2 
deficiency in hepatocytes (LDKO) have been described (Das et al., 2011, Das 
et al., 2009). Genotypes were identified by PCR analysis of genomic DNA 
isolated from mouse-tails. All experiments were performed in male mice. For 
tumor studies, Ppara-/- and WT mice on postnatal day 14 received a single i.p. 
injection of 50 mg/kg body weight diethylnitrosamine (DEN, Sigma-Aldrich) 
dissolved in saline. Six weeks after DEN treatment, mice were put on a high-fat 
diet (HFD, Research Diet Inc.) or standard chow diet ad libitum until sacrifice 8 
months after DEN injection. One group of HFD-fed mice was used for Kaplan-
Meier analysis. For acute response studies, 6-week-old Ppara-/- and WT mice 
were fed a HFD for 13 weeks, given a single 100 mg/kg body weight i.p. 
injection of DEN, and sacrificed after 48 hours. Radiation chimeras were 
generated by exposing 2-month-old DEN-injected recipient mice to 2 x 650 Gy 
ionizing radiation and reconstituting with 2x107 cells from donor bone marrow by 
tail vein injection. Two weeks after bone marrow transplant, mice were fed a 
HFD ad libitum until sacrifice 8 months after DEN injection. Before sacrifice, 
body weight was measured and blood samples were taken for analysis of 
ALT/AST and cytokines. In all cases, mice were euthanized after overnight 
starvation. Mice were housed in a pathogen-free animal facility and kept on a 
12-hour light/dark cycle at constant temperature and humidity.  
For partial hepatectomy (PHx) experiments 6-week-old mice were HFD-fed 
during 6 weeks. Mice were anesthetized using a mixture of isoflurane and 
oxygen. Two-thirds of the liver was excised according to Mitchell and 
Willenbring (Mitchell and Willenbring, 2008), medial and left lateral lobes were 
removed. Mice were sacrificed 48 hours or 15 days after PHx and their liver was 
weighted to analyzed hepatic mass regeneration. 
All animal experiments conformed to EU Directive 2010/63EU and 
Recommendation 2007/526/EC, enforced in Spanish law under Real Decreto 
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53/2013 and the Institutional Animal Care and Use Committee (IACUC) of the 
University of Massachusetts Medical School approved all studies using animals. 
Serum analysis 
Serum activities of ALT and AST were assessed with the ALT and AST 
Reagent Kit (Biosystems Reagents) using a Benchmark Plus Microplate 
Spectrophotometer (Biorad). Serum cytokine concentrations were measured by 
multiplexed ELISA with a Luminex 200 analyzer (Millipore). 
Biochemical analysis 
Total liver proteins were extracted in lysis buffer (50 mM Tris-HCl pH 7.5, 1 mM 
EGTA, 1 mM EDTA pH 8.0, 50 mM NaF, 1 mM sodium glycerophosphate, 5 
mM pyrophosphate, 0.27 M sucrose, 1% Triton X-100, 0.1 mM PMSF, 0.1% 2-
mercaptoethanol, 1 mM sodium-ortovanadate, 1 µg/ml leupeptin, 1 µg/ml 
aprotinin). Extracts were separated by SDS–PAGE and transferred to 0.2 µm 
pore size nitrocellulose membranes (Bio Rad). Blots were probed with primary 
antibodies to caspase-3 (#9662), cleaved caspase-3 (#9661), phospho ERK 
(#9101), ERK (#9102), phospho JNK (#9255), JNK (#9252), phospho STAT3 
(#9145), phospho Akt T308 (#9275), phospho Akt S473 (#9271), Akt (#9272), 
all from Cell Signaling Technology; PCNA (ab1897, Abcam); p53 (sc-99, Santa 
Cruz Biotechnology); and Vinculin (V4505, Sigma). All antibodies were used at 
1:1000 dilution except for anti-p53, which was diluted 1:500. After washes, 
membranes were incubated with an appropriate horseradish peroxidase-
conjugated secondary antibody (GE Healthcare), and signal was detected using 
an enhanced chemiluminescent substrate for the detection of horseradish 
peroxidase (Clarity Western ECL substrate; Biorad).  
Histochemistry 
Liver and tumor tissues were fixed with 10% formalin and embedded in paraffin. 
Sections were cut (4 µm) and stained with hematoxylin and eosin (American 
Master Tech Scientific) for histopathological examination. Sections were also 
incubated with Bouin’s fluid overnight, counter-stained with hematoxylin 
(Sigma), and then stained with Masson-Trichrome stain (American Master Tech 
Scientific). Cell proliferation was assessed by immunohistochemical staining for 
PCNA (ab1897, Abcam) according to the manufacturer’s instructions.  
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Real time q-PCR 
Total RNA was isolated from liver and tumor tissue using the RNeasy Mini Kit 
(Qiagen) with on-column DNase I-digestion. Complementary DNA was 
synthesized with the High-Capacity Complementary DNA Reverse Transcription 
Kit (Applied Biosystems). Sequences of primers used for quantitative real-time-
polymerase chain reaction (qRT-PCR) are provided in Table II. Expression 
levels were normalized to Gapdh mRNA. qRT-PCR was performed using the 
Fast SYBR Green system (Applied Biosystems) in a 7900HT Fast Real-time 
PCR thermal cycler (Applied Biosystems). A dissociation curve program was 
employed after each reaction to verify purity of the PCR products.  
Statistical analysis 
Differences between groups were examined for statistical significance using 2-
tailed Student’s t-test or ANOVA coupled to Bonferroni’s post-test. Kaplan-Meier 
analysis was performed using the log-rank test. 
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TABLE II – qRT-PCR primers 
GENE Forward Primer Reverse Primer 
Cdk2 CCTGCTCATTAATGCAGAGGG GTGCTGGGTACACACTAGGTG 
CcnA1 GCCTTCACCATTCATGTGGAT TTGCTGCGGGTAAAGAGACAGAG 
Foxm1 CTGATTCTCAAAAGACGGAGGC TTGATAATCTTGATTCCGGCTGG 
Cdc25c ATGTCTACAGGACCTATCCCAC ACCTAAAACTGGGTGCTGAAAC 
Trp53 CTCTCCCCCGCAAAAGAAAAA CGGAACATCTCGAAGCGTTTA 
p21 CCTGGTGATGTCCGACCTG CCATGAGCGCATCGCAATC 
p57 CGAGGAGCAGGACGAGAATC GAAGAAGTCGTTCGCATTGGC 
p19 CTGAACCGCTTTGGCAAGAC GCCCTCTCTTATCGCCAGAT 
Lyz2 ATGGAATGGCTGGCTACTATGG ACCAGTATCGGCTATTGATCTGA 
Elane AGCAGTCCATTGTGTGAACGG CACAGCCTCCTCGGATGAAG 
Emr1 CCCCAGTGTCCTTACAGAGTG GTGCCCAGAGTGGATGTCT 
Il6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
Il1b GCAACTGTTCCTGAATCAACT ATCTTTTGGGGTCCGTCAACT 
Tnfa CCCTCACACTCAGATCATCTTCT GCTACGACGTGGGCTACAG 
Il10 GCTCTTACTGACTGGCATGAG CGCAGCTCTAGGAGCATGTG 
Ccl2 TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT 
Ccl3 TTCTCTGTACCATGACACTCTGC CGTGGAATCTTCCGGCTGTAG 
Gapdh TGAAGCAGGCATCTGAGGG CGAAGGTGGAAGAGTGGGA 
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Epidemiological studies have established a strong association between excess 
of body adiposity and increased cancer risk (Renehan et al., 2008).  Obesity 
induces the activation of the stress-activated protein kinase JNK1 (Hirosumi et 
al., 2002). JNK1 activation in the adipose tissue of HFD-fed mice promotes liver 
insulin resistance and steatosis by increasing the circulating levels of the 
inflammatory cytokine IL-6 (Sabio et al., 2008). Inflammation is a well-known 
driver of cancer, and hepatocellular carcinoma (HCC) is a classical model of 
inflammation-linked malignancy (Maeda et al., 2005). Thus, we evaluated the 
role of adipose tissue JNK1 in the development of HCC. To pursue this goal we 
took advantage of a mouse model with specific Jnk1 deficiency in the adipose 
tissue (Sabio et al., 2008). The experimental mouse model was generated by 
crossing mice in which JNK1 gene was flanked by LoxP sequence (Jnk1f/f) with 
mice expressing Cre recombinase under the control of adipose tissue specific 
Fabp4 promoter (Fabp4-Cre) (He et al., 2003). To increase the LoxP sequence 
recombination and achieve a better depletion of Jnk1 gene, we crossed these 
mice with full knock out Jnk1 mice (Jnk1-/-) obtaining one depleted allele and the 
other with LoxP sequence (Fabp4-Cre+Jnk1f/-, FKO mice).  Littermates without 
conditional Jnk1 allele (Fabp4-Cre+ Jnk1+/-) were used as control mice (FWT). 
The specificity of Cre-mediated gene inactivation largely depends on the 
regulatory sequences used to control its expression. However, in some cases, 
unspecific recombination have been observed in tissues (Schmidt-Supprian and 
Rajewsky, 2007). Therefore, we systematically analyzed JNK1 expression at 
protein level in order to validate our genetic model. Lysates from several tissues 
of FKO, FWT and control of depletion Jnk1-/- mice were analyzed by western blot. 
JNK1 levels were decreased in adipose tissue from FKO in comparison with FWT 
indicating a partial depletion of JNK1 in FKO mice in adipocytes (Figure R1A), 
while the expression of JNK1 in other tissues was maintained (Figure R1B).  
These results confirmed that the depletion of JNK1 is partial but tissue-specific. 
This residual expression of JNK1 in adipose tissue of FKO mice could be due to 
the presence of other non-adipocyte cells. 
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Figure R1. JNK1 expression analysis in organs from F
WT
 and F
KO
 mice. 
JNK1 expression was assessed by western blot in several tissues from control (F
WT
) and
 
adipose 
tissue specific JNK1 deficient (F
KO
) mice. Jnk1
-/-
full body knock out organs were used as 
control of depletion. A) Immunoblot analysis of JNK1 in samples of subcutaneous (SC), 
epididymal (EP) and brown adipose tissue from F
WT
, F
KO
 and Jnk1
-/-
 mice. Vinculin protein 
expression was monitored as a loading control. B) Immunoblot analysis of JNK1 in samples of 
liver, muscle, pancreas and bone marrow from F
WT
, F
KO
 and Jnk1
-/-
 mice. Vinculin protein 
expression was monitored as a loading control.
 
 
1.1 JNK1 deficiency in adipose tissue does not protect against HCC 
in HFD 
To evaluate whether depletion of JNK1 in the adipose tissue could affect the 
development of HCC, 14 days-old FKO and FWT control mice were injected with 
the carcinogenic compound diethylnitrosamine (DEN). DEN is a chemical 
compound able to induce tumors specifically in liver; in fact, it is metabolized by 
hepatocytes inducing cell death and compensatory proliferation, as well as 
mutations in hepatocytes (Bakiri and Wagner, 2013). Gene expression profiling 
of DEN-derived HCC showed strong similarities to that of human HCC (Lee et 
al., 2004). For this reason it has been extensively used as a model to study 
HCC development in rodents. Six weeks after DEN injection, mice were 
separated in two groups, one fed a normal chow diet (ND) and the other fed a 
high fat diet (HFD), in which 60% of calories were fat-derived. HFD feeding is a 
well-known procedure to induce obesity, diabetes and insulin resistance in mice 
(Park et al., 2010). Mice were sacrificed eight months after DEN injection and 
livers were examined for HCC development (Figure R2A). No changes in body 
weight were observed between HFD-FKO and HFD-FWT mice (Figure R2B). No 
differences between genotypes were appreciated in tumor generation between 
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HFD-fed FKO and HFD-FWT mice (Figure R2C). Moreover, no significant 
changes in tumor number or tumor size were detected (Figure R2D, E). These 
data demonstrate that under HFD condition, lack of JNK1 in adipose tissue 
does not affect liver cancer development. It has been shown that obesity 
induces IL-6 production in adipose tissue (Fried et al., 1998) and JNK1 
depletion in this tissue reduces the expression of IL-6 in HFD (Sabio et al., 
2008). However, our data suggest that IL-6 produced by adipose tissue during 
obesity is not relevant in chemical-induced HCC development.  
 
Figure R2. Effect of adipose tissue JNK1 deficiency on HCC in HFD-fed mice. 
A) Control (F
WT
) and adipose tissue JNK1 knock out (F
KO
) mice were injected i.p. with 
diethylnitrosamine (DEN; 50 mg/kg) on postnatal day 14 and put on a high-fat diet (HFD) 6 
weeks later. B) Body weight (BW) of HFD-fed F
WT
 and F
KO
 mice was measured 8 months after 
DEN injection. C) DEN-induced HCC in HFD-fed control mice (F
WT
) and adipose tissue JNK1-
deficient mice (F
KO
) at 8.5 months of age. D, E) Quantification of tumor number (C) and size 
(D) in HFD-fed DEN-injected F
WT
 and F
KO
 mice. D) The maximum diameter of individual 
tumor nodules (right panel) and the mean width of tumor nodules (left panel) are presented. 
Data are shown as means ± SEM; Student’s t-test; ns= No statistically significant difference; 
n=15-18 
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1.2 JNK1 deficiency in adipose tissue protects against HCC in 
normal diet 
We next evaluated the effect of JNK1 deficiency in the adipose tissue in control 
condition, under chow diet (ND). As expected, the incidence and the size of 
tumors were reduced in ND-fed FWT mice compared with HFD-fed animals 
(Figure R2C and R3A). These data correlate with previous report that 
demonstrated that obesity enhances tumor growth (Park et al., 2010). 
Interestingly, ND-fed FKO mice were protected against HCC development 
compared with ND-fed FWT control mice (Figure R3A). In fact, ND-fed FKO 
presented a smaller number of tumors (Figure R3B) and developed smaller 
lesions than FWT counterparts (Figure R3C). These results indicate that the 
absence of JNK1 in the adipose tissue induces protection against DEN-induced 
HCC development in normal diet condition, but not during HFD.  
 
Figure R3. Effect of adipose tissue JNK1 deficiency on HCC in ND-fed mice. 
Control (F
WT
) and adipose tissue JNK1 knock out (F
KO
) mice were injected i.p. with 
diethylnitrosamine (DEN; 50 mg/kg) on postnatal day 14 and fed with normal chow diet (ND). 
Mice were sacrificed 8 months after DEN injection. A) DEN-induced HCC in HFD-fed F
WT
 and 
F
KO 
at 8.5 months of age. B, C) Quantification of tumor number (B) and size (C) in ND-fed 
DEN-injected F
WT
 and F
KO
 mice. C) The maximum diameter of individual tumor nodules (right 
panel) and the mean width of tumor nodules (left panel) are presented. Data are shown as means 
± SEM; * p<0.05, ** p<0.005; Student’s t-test; n=15-18  
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1.3 Different metabolites profile in FWT and FKO blood  
Cancer cells are proliferative cells that grow continuously. For this reason a 
cancer cell energy requirement is different from that of a non-tumor cell. In fact, 
transformed cells undergo to metabolic reprogramming in order to effectively 
support neoplastic proliferation (Warburg, 1956, Hanahan and Weinberg, 2011). 
Metabolic changes in tumor cells are reflected in circulating metabolites 
(Holmes et al., 2008, Odunsi et al., 2005, Asiago et al., 2010). Thus, to further 
characterize the differences between FKO and FWT mice after chronic-DEN 
treatment, we analyzed serum metabolomics from both genotypes by mass 
spectrometry (MS). Interestingly, serum from FWT and FKO showed dramatic 
differences in their metabolites profiles, indicating alternative tumor metabolism 
between the two genotypes (Figure R4). 
RESULTS 
1. ROLE OF JNK1 IN ADIPOSE TISSUE-LIVER CROSSTALK IN HCC DEVELOPMENT 
86 
 
 
Figure R4. Metabolomics analysis of serum from DEN-treated F
WT
 and F
KO
 mice. 
ND-fed control mice (F
WT
) and adipose tissue JNK1-deficient mice (F
KO
) were injected with 
diethylnitrosamine (DEN; 50 mg/kg) on postnatal day 14 and sacrificed 8 months later. Serum 
metabolites from these mice were analyzed by mass spectrometry. A) Score plot for principal 
components analysis (PCA) model built with the whole data set and with prediction for quality 
controls (QCs) for the metabolites found with positive (right panel) and negative (left panel) 
ionization modes of serum samples from ND-fed F
WT
 (in black) and F
KO
 (in red) mice. B) 
Orthogonal partial least squares-discriminant analysis (OPLS-DA) score plot with positive 
(upper panels) and negative (bottom panels) ionization modes of serum samples from ND-fed 
F
WT
 (in black) and F
KO
 (in red) mice. VIP of OPLS-DA panels are shown in the right part of the 
figure. n=8.  
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1.4 JNK1 deficiency in adipose tissue protects against xenograft 
tumor development 
In order to further assay the role of adipose tissue in cancer development we 
performed a xenograft experiment in ND-fed FKO and ND-fed FWT mice. For this 
purpose we used a murine hepatocellular cell line (Hep53.4), derived from 
DEN-induced HCC in C57BL/6J mice (Kress et al., 1992). We subcutaneously 
injected 5 x 104 Hep53.4 cells in each flank of FWT and FKO mice. Tumor growth 
was monitored over time and at sacrifice. Time-course measurement of tumor 
growth showed that tumor implanted in FKO mice grew with a slower kinetic than 
the ones implanted in FWT mice (Figure 5A). This was also corroborated at final 
point, 5 weeks after cells injection (Figure R5B). These results are consistent 
with the role of JNK1 in adipose tissue observed previously, and suggest that 
JNK1 in adipose tissue controls the production or secretion of circulating 
molecules that could protect against tumor development. 
 
 
Figure R5. Hep53.4 cells 
xenograft in ND-fed F
WT
 
and F
KO
 mice.  
ND-fed control (F
WT
) and 
adipose tissue JNK1 
deficient (F
KO
) mice were 
subcutaneously injected with 
5 x 10
4
 Hep53.4 cells in each 
flank and sacrificed 5 weeks 
later. A) Tumor volume was 
measured every 3-4 days and 
tumor volume is represented. 
B) Mean of tumor volumes at 
sacrifice is represented. Data 
are shown as means ± SEM; 
*** p<0.001; Student’s t-
test; n=18 tumors (9 mice for 
each genotype). 
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1.5 Jnk1 deletion in adipose tissue does not influence liver 
regeneration 
To understand the mechanism by which deficiency of JNK1 in adipose tissue 
protects against liver cancer development, we tested its role in hepatocyte 
proliferation. Two-thirds partial hepatectomy (PHx) is an established model to 
assess liver proliferation capability. After partial hepatectomy, the liver is able to 
restore the loss mass through a complex and well-orchestrated response. In 
fact, PHx triggers a sequence of organized events leading to cell proliferation 
and liver regeneration, beginning with the entrance of differentiated hepatocytes 
in cell cycle (Michalopoulos, 2007). To verify if loss of JNK1 in the adipose 
tissue influences hepatic regeneration, control FWT and FKO mice were 
examined 48 hours or 15 days after PHx. Measurement of liver mass did not 
show any difference between FWT and FKO mice in liver regeneration; in fact, 
FKO mice have the same ability as FWT mice to restore liver size 48 hours 
(Figure R6A) as well as 15 days after PHx (Figure R6B). These data indicated 
that adipose tissue JNK1 depletion does not influence liver proliferation after 
partial hepatectomy. 
 
Figure R6. Liver regeneration after partial hepatectomy in ND-fed F
WT
 and F
KO
 mice.  
10-12-week-old ND-fed control (F
WT
) and adipose tissue JNK1 knock out (F
KO
) mice underwent 
to partial hepatectomy (PHx). Liver mass was analyzed 48 hours (A) and 15 days (B) after PHx. 
Ratio between liver weight (LW) and tibia length (TL) is represented. Data are shown as means 
± SEM; ns= No statistically significant difference; Student’s t-test; n=6.  
 
1.6 Adipose tissue lacking JNK1 is functional and presents normal 
infiltration levels 
Adipose tissue is the main organ for fat storage and it has a high capacity to 
expand in a non-transformed state. To further characterize the mouse model we 
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measured body weight in ND-fed mice. No significant differences in body weight 
were observed between ND-fed FKO and FWT mice (Figure R7A). The same fat 
deposition correlates with similar adipocyte size analyzed by microscopy in 
white adipose tissue samples stained with hematoxylin and eosin (H&E) (Figure 
R7B). Hence, protection from HCC was not due to differences in fat 
accumulation. We hypothesized that lack of JNK1 in the adipose tissue may 
affect adipokines production or fat functionality. Plin is the gene coding for 
perilipin, which is an important regulator of lipid storage. It coats and protects 
lipid droplets from lipases (Tansey et al., 2001); decrease in perilipin expression 
in adipose tissue would indicate increased lipolysis (Tansey et al., 2001). Thus, 
we checked Plin mRNA levels to test white adipose tissue (WAT) functionality. 
FKO mice showed normal levels of Plin transcript (Figure R7C), indicating a 
normal phenotype of WAT and no changes in lipolysis compared with control 
mice.  
 
Figure R7. Body weight and white adipose tissue analysis of ND-fed F
WT
 and F
KO
 mice.  
ND-fed control (F
WT
) and adipose tissue JNK1 knock out (F
KO
) mice were i.p. injected with 
diethylnitrosamine (DEN; 50 mg/kg) at postnatal day 14 and sacrificed 8 months later. A) Body 
weight of ND-fed F
WT
 and F
KO
 mice chronically treated (DEN) or not treated (CTRL) with 
DEN. B) Representative white adipose tissue sections stained with hematoxylin and eosin from 
ND-fed F
WT
 and F
KO
 mice 8 months after DEN injection. Scale bar=100µm C) qRT-PCR 
analysis of perilipin expression in white adipose tissue from ND-fed F
WT
 and F
KO
 mice 8 months 
after DEN injection. mRNA expression was normalized to Gapdh. Data are shown as means 
±SEM; ns= No statistically significant difference. Student’s t-test; n=8. 
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Inflammation has been shown to be an important risk factor for different types of 
cancer (Balkwill and Mantovani, 2001). Macrophage infiltration in adipose tissue 
produces a low-grade inflammatory environment that could favor tumor growth 
(Mayi et al., 2012, Wagner et al., 2012). Hence, we checked WAT infiltration in 
ND-fed FKO and FWT mice. No differences in mRNA levels of three distinct 
macrophage markers, Lyz2, Emr1 and Nos2, were appreciated, indicating 
normal macrophage infiltration levels in ND-fed FKO WAT (Figure R8A). 
Adipocytes and infiltrated macrophages induce inflammation secreting pro-
inflammatory cytokines, such as IL-6, IL-1β and TNFα, molecules that have 
been shown to promote liver tumor (Maeda et al., 2005). Moreover, JNK1 is a 
key regulator of the expression of several cytokines (Das et al., 2009). To 
analyze whether lack of JNK1 could affect adipose tissue production of 
cytokines we measure by qRT-PCR the expression levels of Il1b, Tnfa and Il6. 
FKO mice showed decreased expression of Il1b and Tnfa mRNA compared with 
FWT counterparts (Figure R8B). However, this reduction in gene expression was 
not reflected in blood circulating levels of these cytokines (Figure R8C), 
suggesting that these transcriptional changes could not be responsible of the 
protection observed in FKO mice. 
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Figure R8. Macrophage infiltration in white adipose tissue and circulating cytokines 
analysis in ND-fed F
WT 
and F
KO
 mice. 
ND-fed control (F
WT
) and adipose tissue JNK1 knock out (F
KO
) mice were i.p. injected with 
diethylnitrosamine (DEN; 50 mg/kg) at postnatal day 14 and sacrificed 8 months later. A) White 
adipose tissue qRT-PCR analysis of macrophage infiltration markers expression, Lyz2, Emr1 
and Nos2. B) White adipose tissue qRT-PCR analysis of cytokines expression, Tnfa, Il1b and 
Il6. mRNA expression was normalized to Gapdh. Data are shown as means ±SEM; * p<0.05, 
ns= No statistically significant difference; Student’s t-test; n=8. C) Luminex analysis of 
circulating TNFα, IL-1β and IL-6. Data are shown as means ±SEM; * p<0.05, ns= No 
statistically significant difference; Student’s t-test; n=17-20. 
 
1.7 Increased circulating adiponectin in FKO mice 
The adipose tissue is an important secreting organ; it produces and releases a 
variety of circulating molecules known as adipokines to the blood stream 
(Gavrilova et al., 2000). Among them, adiponectin is one of the most important 
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adipose tissue-secreted molecules (Maeda et al., 1996). JNK1 full-body knock 
out animals present higher circulating levels of adiponectin (Hirosumi et al., 
2002). Furthermore, circulating adiponectin is reduced in obesity (Arita et al., 
1999), a well-known risk factor for HCC development (Calle et al., 2003). Thus, 
we analyzed whether lack of JNK1 in adipose tissue results in increased 
adiponectin levels. Measurement of adiponectin levels in serum indicated that 8 
months DEN-injected FKO mice had higher circulating levels of this adipokine 
than FWT counterparts (Figure R9A). In particular, low molecular weight (LMW) 
adiponectin was increased in blood from FKO mice in comparison to FWT serum 
(Figure R9B), pointing out the possible role of adiponectin in the observed 
phenotype. 
 
Figure R9. Circulating adiponectin levels in ND-fed F
WT
 and F
KO
 mice. 
ND-fed control (F
WT
) and adipose tissue JNK1 knock out (F
KO
) mice were i.p. injected with 
diethylnitrosamine (DEN; 50 mg/kg) at postnatal day 14 and sacrificed 8 months later. Serum 
from F
WT
 and F
KO
 mice were analyzed for adiponectin levels. A) Immunoblot quantification of 
total circulating adiponectin in ND-fed F
WT
 and F
KO
 mice. Data are shown as means ±SEM; *** 
p<0.001; Student’s t-test; n=9-12. B) Immunoblot quantification of low molecular weight 
(LMW) and high molecular weight (HMW) adiponectin in ND-fed F
WT
 and F
KO
 mice. Data are 
shown as means ±SEM; *** p<0.001; One-way ANOVA coupled to Bonferroni’s post-test; 
n=9-11. 
 
1.8 Adiponectin depletion reverts the phenotype of FKO mice. 
To evaluate whether higher adiponectin levels were sufficient to protect FKO 
mice from HCC development, we abolished adiponectin production in FKO and 
FWT mice genetically, by crossing them with adiponectin full-body knock out 
mice (Adipoq-/-). We analyzed tumor growth in xenograft experiments in adult 
FKOAdipoq-/- (Fabp4-Cre+Jnk1f7-Adipoq-/-) and control FWTAdipoq-/- (Fabp4-
Cre+Jnk1+/-Adipoq-/-) mice. Tumor growth was monitored over time and at 
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sacrifice. Measurement of tumor size showed a comparable xenograft pace of 
growth in FWTAdipoq-/- and FKOAdipoq-/-. This was corroborated 5 weeks after 
Hep53.4 cells injection, when we observed indistinguishable tumor sizes in 
FKOAdipoq-/- and FWTAdipoq-/- (Figure R10). In conclusion, ablation of 
adiponectin was sufficient to revert the protection observed in FKO mice. This 
result suggests that adiponectin is a key player in the protection observed in FKO 
mice.  
 
Figure R10. Hep53.4 cells xenograft in F
WT
Adipoq
-/-
 and F
KO
Adipoq
-/-
 mice. 
Adiponectin knock out mice were crossed with adipose tissue JNK1 deficient mice and control 
mice to obtain F
WT
Adipoq
-/- 
and F
KO
Adipoq
-/-
 mice. F
WT
Adipoq
-/-
 and F
KO
Adipoq
-/-
 mice were 
subcutaneously injected with 5 x 10
4
 Hep53.4 cells in each flank and sacrifice 5 weeks later. A) 
Tumors were measured every 3-4 days and tumor volume is represented. B) Means of tumor 
volume at sacrifice are represented. Pictures from representative tumor are presented. Data are 
shown as means ± SEM; ns= No statistically significant difference; Student’s t-test; n=18-20 
tumors (9-10 mice for each genotype).  
 
To further verify that high adiponectin levels in FKO animals were necessary to 
protect FKO mice against chemical-induced HCC, 14 days old FKOAdipoq-/- mice 
and FWTAdipoq-/- littermates were DEN-treated and sacrificed 8 months after 
injection. Tumor analysis revealed that adiponectin deficiency induced a 
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complete rescue of FKO phenotype. Indeed, FKOAdipoq-/- mice showed similar 
susceptibility to DEN-induced HCC development to FWTAdipoq-/- mice (Figure 
R11A). Number and size of tumors lesions was not statistically different 
between genotypes (Figures R11B and R11C). These results strongly indicate 
that adiponectin is the circulating molecule responsible of the protection against 
HCC development observed in FKO.  
 
Figure R11. HCC development in F
WT
Adipoq
-/-
 and F
KO
Adipoq
-/-
. 
Adiponectin knock out mice were crossed with adipose tissue JNK1 deficient mice and control 
mice to obtain F
WT
Adipoq
-/- 
and F
KO
Adipoq
-/-
 mice. F
WT
Adipoq
-/- 
and F
KO
Adipoq
-/-
 mice 
were injected i.p. with diethylnitrosamine (DEN; 50 mg/kg) on postnatal day 14 and sacrificed 8 
months later. A) DEN-induced HCC in and mice at 8.5 months of age.   B, C) Quantification of 
tumor number (B) and size (C). C) The maximum diameter of individual tumor nodules (right 
panel) and the mean width of tumor nodules (left panel) are presented. Data are shown as means 
± SEM; ns= No statistically significant difference; Student’s t-test; n=10-15  
 
1.9 Adiponectin signaling is induced in livers from FKO mice 
Adiponectin receptor 1 and 2 (AdipoR1, AdipoR2) transduce adiponectin 
signaling into a cellular response (Yamauchi et al., 2007). In fact, once 
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adiponectin binds to AdipoR1 and AdipoR2, they induce 5’ AMP-activated 
protein kinase α (AMPKα) phosphorylation and activation (Yamauchi et al., 
2002). In order to study the molecular mechanism by which adiponectin controls 
tumor progression, 14-days-old FWT and FKO mice were injected with DEN and 
sacrificed 15 days later. As 8 months DEN-treated mice (Figure R7A), no 
differences between genotypes were observed in body weight 15 days DEN 
post-injection (Figure R12A).  
 
Figure R12. Adiponectin signaling in liver from F
WT
 and F
KO
 after DEN treatment  
ND-fed control and adipose tissue JNK1 knock out mice were i.p. injected with 
diethylnitrosamine (DEN; 50 mg/kg) at postnatal day 14 and sacrificed 15 days later. A) Body 
weight analysis of DEN treated (DEN) or not treated (CTRL) F
WT
 and F
KO
 mice. B) 
Immunoblot analysis of adiponectin signaling pathway in liver samples from ND-fed F
WT
 and 
F
KO
 mice. Membranes were probed against P-AMPKα, AMPKα, P-p38α and p38α. Vinculin 
protein expression was monitored as loading control. C, D) Quantification of p38α (C) and 
AMPKα (D) phosphorylation in DEN treated animals. Data are shown as means ±SEM; * 
p<0.05. Student’s t-test; n=3. 
 
To check adiponectin-signaling activation in hepatocytes, we homogenized 
whole liver samples from FWT and FKO mice and tested them for AMPKα 
phosphorylation. We observed a stronger phosphorylation of AMPKα in livers 
from FKO mice compared with FWT counterparts (Figure R12B, C). It has been 
shown that activation of AMPKα is able to promote p38α phosphorylation (Mao 
et al., 2006, Li et al., 2005), and p38α activation is known to suppress cancer 
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cells proliferation (Hui et al., 2007, Iyoda et al., 2003). Thus, we analyze p38α 
activation in liver lysates. An increase in the level of phosphorylated p38α was 
observed in livers from FKO mice compared with FWT mice (Figure R12B, D). 
Together, these data indicate that adiponectin signaling is indeed enhanced in 
FKO livers. 
1.10 AMPKα activation inhibits tumor growth 
To assess the role of AMPKα activation in FKO mice phenotype, C57BL/6J wild 
type mice were treated with an AMPK activator, metformin (Hawley et al., 
2002), in drinking water (300 mg/day/kg of body weight) starting one week 
before the subcutaneous injection of 5 x 104 cells of Hep53.4 cell line. 
Treatment with metformin was maintained during all the experiment. 
Measurement of tumors volume at sacrifice showed that metformin treatment 
reduced tumor growth compared with control drinking water (Figure R13). This 
result indicates that AMPKα activation is sufficient to decrease tumor growth 
and that protects against tumor development. 
 
Figure R13. Hep53.4 cells xenograft in water or metformin treated C57BL/6J mice.  
C57BL/6J mice were treated with metformin in drinking water (300 mg/day per kilogram of 
body weight) and subcutaneously injected with 5 x 10
4
 Hep53.4 cells in each flank. Mice were 
sacrificed 3 weeks after inoculation and xenograft volume was calculated for each tumor. 
Control mice were given normal water. Mean of tumor volumes at sacrifice are represented. 
Data are shown as means ± SEM; ** p<0.01; Student’s t-test; n=20 tumors (10 mice for each 
genotype).  
 
1.11 Constitutive active p38α blocks tumor growth 
To evaluate the role of p38α activation in HCC development, and whether the 
activation of p38α by adiponectin could be responsible of the FKO phenotype, 
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C57BL/6J wild type mice were subcutaneously injected with 5 x 104 cells of 
Hep53.4 cell line. Nine days later, retroviruses expressing a constitutive active 
form of p38α or a control virus were injected directly in the tumor. A second 
virus dose was delivered 14 days after. Measurement of tumors volume at 
sacrifice showed that virus expressing the active p38α significantly reduced 
tumor growth compared with control virus (Figure R14). This result indicates 
that p38α activation is sufficient to decrease tumor growth and protects against 
tumor development.  
 
Figure R14. Hep53.4 cells xenograft treated with retrovirus expressing p38α constitutively 
active form.  
C57BL/6J mice were treated subcutaneously injected with 5 x 10
4
 Hep53.4 cells in each flank. 
Tumors were treated with a retrovirus expressing constitutively active p38α or an empty vector, 
as a control, 9 and 22 days after inoculation. Mice were sacrificed 1 week after the second virus 
treatment and xenograft volume was calculated for each tumor. Mean of tumor volumes at 
sacrifice are represented. Data are shown as means ± SEM; *** p<0.001; Student’s t-test; n=20 
tumors (10 mice for each genotype).  
 
1.12 RNA-sequencing reveals TRAIL as another possible mediator of 
tumor protection 
JNK1 phosphorylates a wide variety of protein targets, including numerous 
transcription factors, to mediate the appropriate cell response to the external 
stimulus (Davis, 2000, Chang and Karin, 2001). Thus, we asked whether other 
molecules regulated by JNK1 in adipose tissue could also being affecting tumor 
development. Changes in the gene expression pattern in adipose tissue from 
FKO and FWT chronically-treated with DEN (8 months after carcinogen injection) 
were assessed by RNA-sequencing. Surprisingly, despite the RNA-sequencing 
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was performed in adipose tissue, gene ontology analyses indicated that genes 
related with liver diseases and malignancies were downregulated in FKO 
adipose tissue in comparison with FWT (Figure R15).  
 
Figure R15. Adipose tissue RNA-sequencing from ND-fed F
WT
 and F
KO
 mice. 
Gene expression of adipose tissue from ND-fed control (F
WT
) and adipose tissue JNK1 deficient 
(F
KO
) mice 8 months after diethylnitrosamine treatment (50 mg/kg) was assessed by RNA-
sequencing and results analyzed by Ingenuity® Pathway Analysis. Graphical representation of 
signaling pathways by their participation in diseases.  
 
Among the overexpressed genes we focused in those coding for secreted 
proteins with a potential anti-tumor effect. We found three genes that were 
slightly overexpressed in FKO adipose tissue compared with controls and that 
encode for bloodstream secreted proteins: Rasal2, SerpinE1 and Tnfsf10. 
These results were validated by qRT-PCR. We observed a significant increase 
of Tnfsf10 and Serpine1 expression in FKO adipose tissue by qRT-PCR, while 
no differences were found in Rasal2 expression (Figure R16).  
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Figure R16. qRT-PCR RNA-seq validation of Tnfsf10, Serpine1 and Rasal2 in adipose 
tissue from ND-fed F
WT 
and F
KO
. 
Control (F
WT
) and adipose tissue JNK1 deficient (F
KO
) mice were injected with 
diethylnitrosamine (DEN; 50 mg/kg) at postnatal day 14 and sacrificed 8 months later. Gene 
expression of adipose tissue from ND-fed F
WT
 and F
KO
 mice 8 months after DEN treatment was 
assessed by RNA-sequencing. Tnfsf10, Serpine1 and Rasal2 expression were assessed by qRT-
PCR. mRNA expression was normalized to Gapdh. Data are shown as means ±SEM; * p<0.05, 
ns= No statistically significant difference; Student’s t-test; n=8 
 
Tnfsf10 gene encodes for TNF-related apoptosis inducing ligand (TRAIL). 
TRAIL is a type II membrane protein belonging to TNF superfamily (Wiley et al., 
1995, Pitti et al., 1996, Marsters et al., 1996). It is present as a cell surface 
protein or as a soluble molecule released to bloodstream (Wiley et al., 1995). 
TRAIL is able to induce apoptosis specifically in cancer cells but not in normal 
cells (Ashkenazi et al., 1999). Next, we asked if TRAIL could also have a role in 
FKO mice protection against HCC development. It has been shown that TRAIL-
induced apoptosis in cancer cells is mediated, at least partially, by RIP1 
(receptor interacting protein 1) activation, followed by p38α phosphorylation 
(Azijli et al., 2013). As previously showed, we observed an increase in p38α 
activation in livers from FKO mice 15 days after DEN injection (Figure R12B, C). 
A group of FWT and FKO mice were DEN-injected and sacrificed 1 month later. 
Livers from FKO mice after DEN-treatment showed increased p38α activation 
compared with FWT counterparts (Figure R17A, B).  
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Figure R17. TRAIL signaling 
analysis in livers from ND-fed F
WT
 
and F
KO
 mice.  
Control (F
WT
) and adipose tissue 
JNK1 deficient (F
KO
) mice were 
injected with diethylnitrosamine 
(DEN; 50 mg/kg) at postnatal day 14 
and sacrificed 1 month later. A) 
Immunoblot analysis of p38α 
phosphorylation in liver from ND-
fed F
WT
 and F
KO
 mice. Blots were 
probed with P-p38α and p38α 
antibodies. Vinculin protein 
expression was monitored as loading 
control. B) Quantification of p38α 
phosphorylation. Data are shown as 
means ±SEM; * p<0.05. Student’s t-
test. 
 
However, it has been shown that cancer cells can avoid TRAIL-induced 
apoptosis through FLICE-inhibitory protein (FLIP), which inhibits caspase-8 
activity (Irmler et al., 1997, Zhang and Fang, 2005). We tested the levels of 
FLIP in tumors from FKO and FWT control mice. We observed a reduction in FLIP 
protein in FKO mice compared with FWT (Figure R18A, B). These results indicate 
that tumors raised in FKO mice might be more prone to undergo to TRAIL-
mediated apoptosis compared with FWT ones. 
 
Figure R18. FLIP expression 
analysis in tumors from ND-fed 
F
WT
 and F
KO
 mice.  
Control (FWT) and adipose tissue 
JNK1 deficient (FKO) mice were 
injected with diethylnitrosamine 
(DEN; 50 mg/kg) at postnatal day 14 
and sacrificed 8 months later. A) 
Immunoblot analysis of FLIP 
expression in tumors from ND-fed 
F
WT
 and F
KO
 mice. Vinculin protein 
expression was monitored as 
loading. B) Quantification of FLIP 
expression. Data are shown as means 
±SEM; * p<0.05. Student’s t-test. 
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Obesity has been linked with increased incidence of liver cancer (Klein et al., 
2014, Calle et al., 2003). However, little is known about how obesity reshapes 
liver metabolism during tumor development. High fat diet (HFD) consumption 
changes hepatic gene expression through activation of the transcription factor 
peroxisome proliferator-activated receptor α (PPARα) (Memon et al., 2000). 
Thus, we investigated the role of PPARα during hepatocellular carcinoma 
(HCC) development. We used full-body knock out Ppara mice (Ppara-/-) and we 
compared them with wild type C57BL/6 mice (WT). 
2.1 PPARα deficiency protects against DEN-induced HCC 
development in HFD-fed mice 
To study the role of PPAR in DEN-induced HCC in the context of obesity, we 
administered diethylnitrosamine (DEN) to WT and Ppara-/- mice on postnatal 
day 14, and 6 weeks later we placed the animals on either a normal chow diet 
(ND) or a high-fat diet (HFD), in which 60% of calories are fat-derived. HCC 
insurgence was monitored 8 months after DEN injection (Figure R19A). On the 
normal chow diet, the two genotypes showed no statistically significant 
differences in body weight (Figure R19B) and in tumor number or size (Figure 
R19C, D). In contrast, HFD-fed Ppara-/- mice were protected against HFD-
induced obesity (Figure R20A). Moreover, they showed a strong protection 
against HCC development (Figure R20B); in fact, the mean number of tumors 
per animal was lower in Ppara-/- mice compared with WT counterparts (Figure 
R20C). Additionally, tumors were smaller in Ppara-/- mice than in WT mice 
(Figure R20D). Such protection against HCC development in HFD-fed Ppara-/- 
mice also correlated with better survival (Figure R20E). Collectively, these data 
indicate that absence of PPARα protects against DEN-induced HCC in HFD-fed 
mice, but not during normal diet. 
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Figure R19. Effect of PPARα deficiency on HCC in ND-fed animals 
A) WT and Ppara
-/-
 mice were i.p. injected on postnatal day 14 with diethylnitrosamine (DEN; 
50 mg/kg) and put on a high-fat diet (HFD) or normal chow diet (ND) 6 weeks later. Mice were 
sacrificed 8 months after DEN injection. B) Body weight (BW) of ND-fed WT and Ppara
-/-
 
mice 13 months after DEN injection. C, D) Quantification of tumor number and size in ND-fed 
DEN-injected WT and Ppara
-/-
 mice. The maximum diameter of individual tumor nodules (right 
panel) and the mean width of tumor nodules (left panel) are presented. Data are shown as means 
± SEM; ns=No statistically significant difference (Student’s t-test; n=8-14). 
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Figure R20. Effect of PPARα deficiency on HCC in HFD-fed animals 
WT and Ppara-/- mice were i.p. injected on postnatal day 14 with diethylnitrosamine (DEN; 50 
mg/kg) and put on a high-fat diet (HFD) 6 weeks later. Mice were sacrificed 8 months after 
DEN injection. A) Body weight (BW) of HFD-fed WT and Ppara-/- mice 8 months after DEN 
injection. B) DEN-induced HCC in HFD-fed WT and Ppara-/- mice at 8.5 months of age. C, D) 
Quantification of tumor number and size in HFD-fed DEN-injected WT and Ppara-/- mice. The 
maximum diameter of individual tumor nodules (right panel) and the mean width of tumor 
nodules (left panel) are presented. Data are shown as means ± SEM; ** p<0.005, *** p<0.001 
(Student’s t-test; n=25). E) Kaplan-Meier analysis of the survival of HFD-fed DEN-injected WT 
and Ppara
-/-
 mice; ***p<0.001 (Mantel-Cox log-rank test; n=9-10). 
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2.2 Lack of PPARα does not influence liver regeneration 
A well-studied model to assess liver proliferation avoiding hepatocyte cell death 
is two-thirds partial hepatectomy. After partial liver resection, mature 
hepatocytes are able to enter cell cycle and regenerate the loss tissue 
(Michalopoulos, 2007). Therefore we checked the capacity of HFD-fed Ppara-/- 
liver to regenerate after partial hepatectomy (PHx). Six-week-old WT and  
Ppara-/- mice were fed with HFD during six weeks before surgery (Figure R21A). 
No differences were observed between Ppara-/- and WT liver mass, nor 48 
hours (Figure R21B) neither 15 days after PHx (Figure R21C). However,  
Ppara-/- mice showed increased mortality after PHx compared with WT 
counterparts (Figure R20D). It has been showed that PPARα is necessary in 
the inflammatory phase of wound healing and its absence causes a delay in the 
healing that could explain the increased mortality after surgery (Michalik et al., 
2001). Despite Ppara-/- mice were adversely affected by PHx their livers were 
able to regenerate. These results suggest that lack of PPARα does not 
influence mature hepatocytes capability to enter cell cycle.  
 
 
Figure R21. Liver regeneration after partial hepatectomy in HFD-fed WT and Ppara
-/-
 
mice.  
A) Six-week-old WT and Ppara
-/-
 mice were fed a high-fat diet (HFD) during 6 weeks before 
partial hepatectomy (PHx). B, C) Liver mass was analyzed 48 hours (B) and 15 days (C) after 
PHx in HFD-fed WT and Ppara
-/-
 mice. Ratio between liver weight (LW) and tibia length (TL) 
is represented. Data are shown as means ± SEM; ns= No statistically significant difference; 
Student’s t-test; n=15-8 (B); n=9-6 (C). D) Representation of mortality percentage after PHx of 
HFD-fed WT and Ppara
-/-
 mice. 
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2.3 Ppara deletion protects from liver damage on HFD 
Contrary to partial hepatectomy, DEN treatment induces hepatocyte death 
associated with enhanced compensatory proliferation and augmented HCC 
development (Maeda et al., 2005, Hui et al., 2007, Das et al., 2011). To assay 
whether lack of PPARα on HFD could affect hepatocyte cell death we evaluated 
liver damage after acute DEN injection in HFD-fed animals (Figure R22A). 
Measurement of blood levels ALT and AST revealed less liver damage in 
Ppara-/- mice than in WT counterparts (Figure R22B). 
 
Figure R22. Liver damage analysis after acute DEN treatment on HFD-fed WT and  
Ppara
-/-
 mice.  
A) WT and Ppara
-/-
 mice were fed a high-fat diet (HFD) from 6 weeks of age. At 19 weeks, 
mice were injected i.p. with diethylnitrosamine (DEN; 100 mg/kg) and sacrificed 48 hours later. 
B) Liver damage was assessed from serum measurements of ALT and AST; n=3-7 (3 non-
injected mice and 7 injected mice per genotype). Data are shown as means ± SEM; ** p<0.005; 
*** p<0.001 (one-way ANOVA coupled to Bonferroni’s post-test). 
 
Moreover, DEN-induced apoptosis in liver tissue was reduced in HFD-fed 
Ppara-/- mice as indicated by caspase-3 cleavage (Figure R23A). Different types 
of cell signaling pathways can modulate tumor development. Among them 
Ras/Raf/MEK/ERK and STAT3 pathways have a major role in HCC 
development (Huynh et al., 2003, He et al., 2010), promoting tumor growth and 
inhibiting apoptosis. Thus we checked by western blot ERK and STAT3 
activation. We found both proteins to be less activated in livers from Ppara-/- 
mice (Figure R23B), correlating with reduced proliferation and higher apoptosis 
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(Figure R23A). We next examined activation of JNK, a kinase affected by 
inflammation and obesity and known to modulate HCC development (Hui et al., 
2008, Maeda et al., 2005, Das et al., 2011, Sabio et al., 2009, Han et al., 2016). 
Interestingly, HFD-fed Ppara-/- mice exhibited reduced JNK activity in liver after 
DEN injection. 
 
Figure R23. Signaling analysis in acute DEN-treated HFD-fed in WT and Ppara
-/-
 mice.  
WT and Ppara
-/-
 mice were fed a high-fat diet (HFD) from 6 weeks of age. At 19 weeks, mice 
were injected i.p. with diethylnitrosamine (DEN; 100 mg/kg) and sacrificed 48 hours later. A) 
Immunoblot analysis of caspase3 and cleaved caspase3 in liver samples from untreated (CTRL) 
and acutely DEN-treated (ACUTE DEN) HFD-fed WT and Ppara
-/- 
mice. Vinculin protein 
expression was monitored as a loading control. B) Immunoblot analysis of signaling pathways 
in liver samples from untreated and acutely DEN-treated WT and Ppara
-/- 
mice; blots were 
probed with antibodies to p-ERK, ERK, p-JNK, JNK, and p-STAT3. Vinculin protein 
expression was monitored as a loading control.  
 
Inflammation plays a central role in cancer development. In particular, it has 
been shown that HCC is a typical inflammation-driven malignancy (Maeda et 
al., 2005). To address the role of inflammation in Ppara-/- mice protection from 
liver damage, we checked circulating levels of different pro-inflammatory 
cytokines. Surprisingly, no significant reduction in serum levels of the cytokines 
IL-6, TNF, IL-1β, CCL2, and IFN in HFD-fed Ppara-/- mice were observed, 
suggesting that HFD-fed Ppara-/- protection against acute DEN-induced liver 
damage was not associated with lower inflammation (Figure R24). In contrast, 
after acute DEN injection, HFD-fed Ppara-/- mice showed higher levels of pro-
inflammatory chemokines CXCL2 and CCL3 than WT counterparts (Figure 
R24), correlating with the higher levels of markers of immune cells infiltration in 
tumors 8 months after DEN injection (Figure R25).  
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Figure R24. Circulating cytokines after acute DEN treatment of HFD-fed WT and Ppara
-/-
 
mice.  
WT and Ppara
-/-
 mice were fed a high-fat diet (HFD) from 6 weeks of age. At 19 weeks, mice 
were injected i.p. with diethylnitrosamine (DEN; 100 mg/kg) and sacrificed 48 hours later. 
Luminex analysis of cytokines and chemokines in blood. Data are shown as means ± SEM; * 
p<0.05, ** p<0.005, *** p<0.001. One-way ANOVA coupled with Bonferroni’s post-test 
statistical analysis was performed (n=4-7). 
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Figure R25. Liver and tumor infiltration and cytokines production in chronic-DEN 
treated HFD-fed WT and Ppara
-/-
 mice.  
WT and Ppara
-/-
 mice were i.p. injected on postnatal day 14 with diethylnitrosamine (DEN; 50 
mg/kg) and put on a high-fat diet (HFD) 6 weeks later. They were sacrificed 8 months after 
DEN injection. qRT-PCR analysis of liver and hepatic tumor cytokine and chemokine 
expression in WT and PPARα-/- mice. mRNA expression was normalized to Gapdh and to WT 
liver. Data are shown as means ± SEM; * p<0.05, ** p<0.005, *** p<0.001 (One-way ANOVA 
coupled to Bonferroni’s post-test; n=6). 
 
Obesity is linked to increased incidence of non-alcoholic fatty liver disease 
(NAFLD), which can degenerate in cirrhosis and, subsequently, HCC. Lipid 
peroxidation is an important feature of NAFLD and generates reactive oxygen 
species (ROS) that can induce DNA mutations (Caldwell et al., 2004). Analysis 
of thiobarbituric acid reactive substances (T-BARS), a by-product of lipid 
peroxidation, revealed lower oxidized lipid content in the livers of HFD-fed 
Ppara-/- mice (Figure R26). These results suggest that PPARα in the liver, but 
not in hematopoietic cells, promotes HCC development in HFD-fed WT animals. 
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Figure R26. Lipid peroxidation analysis in livers from HFD-fed WT and Ppara
-/-
 mice.  
WT and Ppara
-/-
 mice were fed a high-fat diet (HFD) from 6 weeks of age. At 19 weeks, mice 
were sacrificed. Lipid peroxidation was analyzed by T-BARS assay in livers from WT and 
Ppara
-/- 
mice. Data are shown as means ± SEM *** p<0.001 (Student’s t-test; n=3). 
 
2.4 Lack of PPARα protects against HCC independently of bone 
marrow. 
PPARα is a transcription factor that is highly expressed in liver, controlling its 
metabolism. It has a central role in the regulation of genes involved in fatty 
acids transport and degradation in mitochondria and peroxisome (Gulick et al., 
1994, Evans et al., 2004). Moreover, PPARα is expressed in immune cells 
where has an anti-inflammatory activity in both mice and humans (Devchand et 
al., 1996, Staels et al., 1998, Clark, 2002). In order to verify in which 
compartment PPARα expression plays a role in HFD-fed Ppara-/- mice 
protection against HCC development, we generated chimera mice transplanting 
WT or Ppara-/- bone marrow (BM) into lethally irradiated WT or Ppara-/- 
recipients (Figure R27A). Chronic-DEN-induced HCC development was strongly 
suppressed in reconstituted Ppara-/- mice compared with reconstituted WT 
mice, irrespective of donor BM genotype (Figure R27B). On the HFD, 
reconstituted Ppara-/- mice also developed significantly smaller tumors than their 
WT counterparts, again irrespective of donor BM genotype (Figure R27C). 
These results indicate that bone-marrow-derived cells do not primarily mediate 
the protection against HCC in HFD-fed Ppara-/- mice, suggesting the 
involvement of a cell-autonomous mechanism 
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Figure R27. HCC development in HFD-fed chimera mice.  
A) WT and Ppara
-/- 
mice were injected i.p. on postnatal day 14 with diethylnitrosamine (DEN; 
50 mg/kg). At 8 weeks of age mice were lethally irradiated and inoculated i.v. with bone 
marrow cells from WT or Ppara
-/-
 mice. Bone marrow donor genotype is indicated as 
superscript. After 2 weeks, mice were placed on high-fat diet (HFD) and sacrificed at 8.5 
months of age. B) DEN-induced liver cancers in WT and Ppara
-/- 
mice transplanted with WT or 
Pparα-/- bone marrow (bone marrow donor genotype is indicated as superscript). The bar chart 
shows mean tumor size, and photographs show representative images of livers from each 
condition. Data are shown as means ± SEM; ** p<0.005, *** p<0.001 (one-way ANOVA 
coupled to Bonferroni’s post-test; n=12-22). 
 
2.5 PPARα deficiency inhibits hepatocyte proliferation 
To define the molecular mechanism underlying HCC protection in HFD-fed 
Ppara-/- mice we examined multiple signaling pathway involved in liver 
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proliferation and cell death in liver and tumor homogenates from chronic DEN-
treated HFD-fed WT and Ppara-/- mice. To identify signaling pathways 
responsible for the reduced liver damage in HFD-fed Ppara-/- mice, we 
examined liver and tumor samples for the activation of protein kinases known to 
be affected by metabolic state. AKT/mTOR signaling pathway is known to be 
sensor of metabolic state of the cell and its activation can induce cell 
proliferation (Deberardinis et al., 2008, Manning and Cantley, 2007). ERK is the 
effector of Ras/Raf/MEK pathway and induces cell proliferation and response to 
oxidative stress (Huynh et al., 2003, He et al., 2010). HFD-fed Ppara-/- mice 
exhibited reduced activation of ERK and AKT, as we observed lower 
phosphorylation levels of both kinases in healthy liver and hepatic tumors from 
HFD-fed Ppara-/- mice (Figure R28). The tumor suppressor p53 coordinates 
anti-proliferative responses that restrict malignant-cell expansion. Lack of p53 
facilitates de-differentiation of mature hepatocytes and correlates with HCC 
(Tschaharganeh et al., 2014). We found that chronic DEN treatment induced 
p53 loss in tumor and liver tissue from HFD-fed WT mice, whereas p53 levels in 
HFD-fed Ppara-/- mice were maintained (Figure R28). 
 
Figure R28. Cell signaling analysis of livers and tumors from chronic-DEN treated HFD-
fed WT and Ppara
-/-
 mice. 
WT and Ppara
-/-
 mice were i.p. injected on postnatal day 14 with diethylnitrosamine (DEN; 50 
mg/kg) and put on a high-fat diet (HFD) 6 weeks later. They were sacrificed 8 months after 
DEN injection.  Immunoblot analysis of ERK, JNK, AKT, their phosphorylated forms, PCNA, 
and p53 in tumors isolated from WT mice and Ppara
-/-
 mice after chronic DEN (liver and tumor 
samples) and not injected controls (CTRL). Vinculin protein expression was monitored as a 
loading control. 
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qRT-PCR analyses of tumor and non-tumor tissues from WT and Ppara-/- mice 
revealed reduced expression of the cell-cycle regulators Cdk2, CcnA1, Foxm1, 
and Cdc25c in non-tumor samples from Ppara-/- mice (Figure R29A) and 
enhanced expression of the cell-cycle regulatory genes p21, Trp53, p19 and 
p57 in Ppara-/- tumor tissue (Figure R29B). This finding strongly suggests lower 
hepatocyte proliferation in Ppara-/- livers.  
 
Figure R29. Cell cycle regulators analysis in livers and tumors from chronic-DEN treated 
HFD-fed WT and Ppara
-/-
 mice. 
WT and Ppara
-/-
 mice were i.p. injected on postnatal day 14 with diethylnitrosamine (DEN; 50 
mg/kg) and put on a high-fat diet (HFD) 6 weeks later. They were sacrificed 8 months after 
DEN injection.  A) qRT-PCR analysis of cyclin and cell cycle regulator expression in liver 
samples from WT and Ppara
-/-
 mice. mRNA expression was normalized to Gapdh and WT liver 
expression. Data are shown as means ± SEM; **p<0.005, *** p<0.001 (Student’s t-test; n=6). 
B) qRT-PCR analysis of cyclin and cell cycle regulator expression in hepatic tumors from WT 
and Ppara
-/-
 mice. mRNA expression was normalized to Gapdh and WT liver expression. Data 
are shown as means ± SEM; **p<0.005, *** p<0.001 (Student’s t-test; n=6). 
 
2.6 PPARα hyperactivation in hepatocytes promotes liver cancer  
JNK suppresses PPAR activity and mice lacking hepatocyte JNK1/2 
expression show elevated PPAR activity and fatty acid oxidation (Vernia et al., 
2014). To determine whether PPAR activation was sufficient to promote liver 
cancer, we examined adult liver from Alb-Cre control (LWT) mice and mice with 
compound JNK1/2 deficiency in hepatocytes (LDKO). At 10 months of age, 
LWT mice showed no evidence of hepatic pathology; in contrast, 82% of LDKO 
RESULTS 
2. ROLE OF PPARα ACTIVATION IN LIVER CANCER 
117 
 
mice displayed multifocal bile duct hyperplasia associated with fibrosis and 
inflammatory cell infiltration (Figure R30). Bile duct epithelial cells from these 
LDKO mice stained positive for the proliferation marker PCNA. The remaining 
LDKO mice exhibited cholangiocarcinoma (6%) or appeared to be healthy 
(12%).  
 
Figure R30. Histological analysis of 10-month-old ND-fed LWT and LDKO mice. 
Histochemical analysis of liver from LWT (Alb-cre control) and LDKO (liver-specific JNK1/2 
deficient) mice fed standard chow diet (ND) for 10 months. Panels show representative liver 
sections stained with hematoxylin and eosin (H&E), antibody to PCNA and Masson’s 
trichrome.  Scale bar = 100 µm. 
 
At 14 months of age, 94% of LDKO mice displayed cholangiocarcinoma 
associated with fibrosis (Figure R31A, D) and increased liver mass (Figure 
R31B), and the remaining LDKO mice (6%) had cystic livers with bile duct 
hyperplasia. Moreover, LDKO mice showed elevated serum ALT levels, 
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indicating liver damage (Figure R31C). Together, these data confirm that 
mature mice with compound deficiency of JNK1 and JNK2 in hepatocytes 
progressively develop cholangiocarcinoma.   
 
Figure R31. Analysis of 14-month-old ND-fed LWT and LDKO mice. 
LWT (Alb-cre control) and LDKO (liver-specific JNK1/2 deficient) mice fed standard chow 
diet (ND) for 14 months. A) Representative livers from chow-fed 14-month-old LWT and 
LDKO mice. B) Liver mass (g) in 14-month-old chow-fed LWT and LDKO mice. Data are 
shown as means ± SEM; *** p<0.001 (Student’s t-test; n=15). C) Liver damage measured by 
ALT in 14-month-old chow-fed LWT and LDKO mice. Data are shown as means ± SEM; 
*p<0.05 (Student’s t-test; n=11). D) Representative H&E and Masson’s trichrome staining on 
liver sections from14-month-old chow-fed LDKO mice. Scale bar = 100 µm.  
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Cancer is a leading cause of death in many high-income countries; moreover 
its incidence is growing in low and middle-income nations (Bray et al., 2012), 
leading to the worldwide increase of morbidity and mortality of this non-
communicable disease. Nowadays therapy options exist for several types of 
malignancies, thanks to early diagnosis and effective treatments (for example 
estrogen responsive breast cancers, melanoma and prostate cancers). 
Nevertheless, other types of malignancies does not benefit of the same 
situations:  diagnosis occurs in late-stages and no curative treatments are 
available for pancreatic cancer, hepatocellular carcinoma, nodular melanoma 
and triple-negative breast cancer, to mention some. Therefore, there is a 
growing attention to newly recognized risk factors for cancer and the 
molecular mechanisms that link them to malignancies. In this scenario, obesity 
and metabolic disorders are becoming major risk factors for different types of 
cancer (hepatocellular carcinoma, gynecological cancers, stomach and colon 
cancer) (Calle et al., 2003, Font-Burgada et al., 2016). Altered metabolism can 
lead to low-grade chronic inflammation, hyperinsulinemia and hyperglycemia 
that together create a favorable environment for cancer development (Font-
Burgada et al., 2016). In particular, a strong causal connection between 
metabolic disorders and hepatocellular carcinoma has been discovered (Calle 
et al., 2003, Baffy et al., 2012). The main purpose of this Thesis was to further 
dissect the connection between metabolism and HCC and unravel the 
contribution of organs crosstalk in HCC development. For this reason, we 
studied the role of two genes involved in metabolism, Jnk1 and Ppara, in liver 
tumorigenesis. 
1. ROLE OF JNK1 IN ADIPOSE TISSUE-LIVER CROSSTALK IN HCC 
DEVELOPMENT 
1.1 IL-6 produced by adipose tissue is not relevant for DEN-
induced HCC 
IL-6 is a pro-inflammatory cytokine that plays a pivotal role in hepatic steatosis 
and HCC development (Sabio et al., 2008, Park et al., 2010). Liver steatosis is 
a common consequence of obesity and it triggers activation of residential 
Kupffer cells increasing pro-inflammatory cytokines production (Park et al., 
2010). It has been described that JNK1 expression in adipose tissue during 
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obesity leads to an increase in IL-6 production and secretion from adipose 
tissue (Sabio et al., 2008). In fact, mice lacking JNK1 in adipose tissue are 
protected against HFD-induced liver steatosis due to a reduction of IL-6 levels 
(Sabio et al., 2008). These results suggest that lack of JNK1 in adipose tissue 
might protect animals against obesity-increased HCC development. However, 
our results show that lack of JNK1 in the adipose tissue does not protect 
against DEN-induced HCC in HFD (Figure R2); in fact, the same number and 
size of tumors were observed in FKO (Fab-Cre+Jnk1f/-) and FWT (Fab-
Cre+Jnk1+/) mice under HFD conditions (Figure R2). A possible explanation of 
these results is that Kupffer cells are the main producers of IL-6 and TNFα in 
this mouse model. In fact, it has been shown that JNK1 regulates TNFα and 
IL-6 expression in Kupffer cells, thus controlling hepatocyte cell death (Das et 
al., 2009).  In FKO mice Kupffer cells have normal levels of JNK1. Thus we can 
hypothesize that the reduction of IL-6 production from adipose tissue of HFD-
FKO mice does not have a strong influence on chemical-induced HCC 
development. Taking into account that both stimuli, HFD and DEN, strongly 
induce a pro-inflammatory environment, it is possible that the decrease of IL-6 
production from adipose tissue might result imperceptible. However, 
understand the role of IL-6 produced by adipose tissue during obesity in HCC 
would be appealing, as it could be a new therapeutic target. For this purpose, 
it would be necessary to use a different experimental model, different from the 
one we used, based on chemical-induced inflammation to provoke cancer 
development. One possibility would be to apply, for example, a genetic model 
of HCC. In fact, mutations in Tpr53 gene are highly frequent in human HCC 
(Fujimoto et al., 2012) and hepatocyte-specific Tpr53 deletion induces HCC in 
5 months with 80% of incidence in mice (Katz et al., 2012). This genetic model 
can be obtained using the CRISPR/Cas9 technology (Seruggia and Montoliu, 
2014). FKO and FWT mice, or alternatively adipose tissue-specific Il6 knock out 
mice, could be crossed with Rosa26-Cas9 knock-in mice (Platt et al., 2014), to 
obtain whole body constitutive expression of Cas9. To obtain liver-specific 
deletion of Trp53 gene, mice can be intravenously injected with hepatocyte-
specific adeno-associated virus (AAV8 or AAV9) carrying the CRISPR guide 
RNA targeting Tpr53 (Trp53 sgRNA). Alternatively, hepatocyte-specific 
delivery of Tpr53 sgRNA can be obtained through hydrodynamic tail vein 
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injection (Zhang et al., 1999). However, both ways of delivery are also 
associated with low grade liver inflammation. It would be opportune to monitor 
the level of inflammation induced. Another alternative experiment to study the 
role of adipose tissue IL-6 in HCC development in the absence of chemical-
induced inflammation consists in the long term feeding of FWT and FKO mice 
with choline-deficient high fat diet (CD-HFD) (Wolf et al., 2014). Wolf and 
colleagues demonstrated that feeding mice with a CD-HFD during 12 months 
induces HCC development with incidence around 25% in C57BL/6 mice. 
Despite the low HCC incidence, this method could be useful to avoid 
experimental-derived inflammation and to study the contribution of adipose 
tissue IL-6 in HCC development during obesity. 
1.2 ND-FKO mice are protected against HCC development and have 
normal liver regeneration after partial hepatectomy 
In contrast with the results obtained with HFD-fed FKO mice, ND-fed FKO mice 
are protected against DEN-induced HCC development; in fact, they showed a 
decrease in both number and size of tumors (Figure R3). These data were 
also confirmed in a xenograft model: FKO mice showed protection against 
tumor growth when injected with Hep53.4 cells, a HCC cell line isolated from 
tumors DEN-induced in C57BL/6J mice (Figure R5). Taken together, these 
data show that JNK1 in adipose tissue promotes liver tumor development, 
indicating a crosstalk between adipocytes and hepatocytes, in which JNK1 
plays an important role. A well-known model to assess hepatocytes 
proliferation is partial hepatectomy (Michalopoulos, 2007). However, we did 
not observe any differences in liver regeneration (Figure R6A, B). These 
results suggest that JNK1 in the adipose tissue does control HCC 
development but does not influence liver regeneration. Together with liver 
transplantation, partial hepatectomy is the most curative therapy for HCC 
(Llovet et al., 2003). However, nearly 80% of patients suffer HCC recurrence 
in 5 years after partial hepatectomy (Yamamoto et al., 1996). Partial liver 
resection induces differentiated hepatocytes to entrance in cell cycle, 
triggering their proliferation until the liver mass is reestablished. On the other 
hand, it is clear that liver regeneration after partial hepatectomy enhances 
HCC recurrence (Man et al., 2007, Picardo et al., 1998). Therefore, it is 
fundamental to balance the protection against HCC recurrence and liver 
DISCUSSION 
1. ROLE OF JNK1 IN ADIPOSE TISSUE-LIVER CROSSTALK IN HCC DEVELOPMENT 
126 
 
regeneration ability. In this context, our model suggests that reducing the 
activity of JNK1 in the adipose tissue could favor such balance. However, 
further experiments are necessary in order to confirm this point. For example 
a study of liver regeneration after tumor resection or, alternatively, intra-
hepatic injection of HCC cells just before partial hepatectomy in FKO and FWT 
mice. Notably, the latter experiment would also mimic the presence of not 
detectable tumor cells in the liver, a possible cause of HCC recurrence in 
patients (Picardo et al., 1998).  
1.3 Different metabolic profile in FWT and FKO mice 
To further dissect the metabolic difference between FKO and FWT mice, we 
analyzed circulating metabolites by serum mass spectrometry (MS). Each of 
the analyzed genotypes showed a unique metabolic signature (Figure R4), 
indicating important differences between FWT and FKO mice. In fact, tumor 
growth induces changes in cell metabolism that are reflected in the 
metabolites produced and secreted in the bloodstream (Holmes et al., 2008, 
Odunsi et al., 2005, Asiago et al., 2010). These results might be relevant in 
the framework of cancer diagnostics. In fact early analytical biomarkers for 
HCC are needed, especially because late diagnosis is responsible of the high 
mortality rate of HCC. For this reason, in the last years, more efforts have 
been made to improve the early diagnosis of this malignancy (Tsuchiya et al., 
2015, Zeng et al., 2015). In this scenario, metabolomics studies of early-
detected HCC represent a valuable resource to the diagnosis of liver cancer. 
However, the main weakness of this analysis is that we cannot discriminate 
between markers of HCC and metabolites differentially produced by FKO and 
FWT mice. It would be useful to examine serum from control FKO and FWT mice 
at the same age. This more extended analysis would also indicate whether 
lack of JNK1 in adipose tissue could affect serum metabolic profile and 
whether any of these metabolites that are differentially expressed could be 
exploited as a potential target of therapy. 
1.4 Adipose tissue from FKO mice is functional 
We observed no differences in body weight of FKO and FWT mice (Figure R7A), 
indicating that the protection against HCC is not caused by a reduction in 
weight gain. Moreover, adipose tissue from both genotypes presented a 
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completely normal structure and functionality (Figure R7B, C), and no 
differences in infiltration were observed (Figure R8A). JNK1 activation in 
adipose tissue has been described to promote pro-inflammatory cytokines 
production during HFD (Sabio et al., 2008, Sun et al., 2011). Thus, we 
analyzed IL-6, TNFα and IL-1β production in adipose tissue. Despite we 
observed a decrease in the expression of TNFα and IL-1β in adipose tissue 
from FKO mice (Figure R8B), these results were not reflected in circulating 
levels of these cytokines (Figure R8C), indicating that cytokines levels are not 
the driving cause of the observed phenotype. 
1.5 Adiponectin protects against HCC development 
Adipose tissue is involved in the production of several molecules, commonly 
referred to as adipokines (Gavrilova et al., 2000). These molecules regulate 
appetite and metabolism. In addition, adipokines are also involved in 
inflammation, cell growth and differentiation. Among them, adiponectin is one 
of the most expressed and most representing (Maeda et al., 1996). Moreover, 
it has been described that JNK1 full knock out mice show an increase in 
adiponectin levels (Hirosumi et al., 2002). Interestingly, adiponectin circulating 
levels are decreased in both HCC and obese state (Kelesidis et al., 2006, 
Arita et al., 1999). We found that adiponectin circulating levels are increased 
in FKO mice compared with FWT counterparts, suggesting a role of adiponectin 
in the observed protection of FKO mice against HCC development (Figure 
R9A, B). Moreover, genetic depletion of adiponectin in FKO and FWT mice 
using adiponectin knock out mice completely reverted FKO protection against 
HCC development, confirming the importance of adiponectin in this model 
(Figure R10A, B and R11). One of the proposed mechanisms in adiponectin-
induced protection against malignancies is the inhibition of cancer cells 
proliferation through the activation of AMPKα signaling (Mao et al., 2006). 
Moreover, it has been showed that transforming growth factor-β-activated 
protein kinase 1-binding protein-1 (TAB1)-AMPKα complex can recruit p38α 
MAPK inducing its auto-phosphorylation (Li et al., 2005). We observed that 
both AMPKα and p38α were more phosphorylated in FKO livers 15 days after 
DEN injection (Figure R12B, C, D). Moreover, metformin-induced AMPKα 
activation (Figure R13) and intra-tumor injection of active p38α retrovirus 
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inhibit tumor growth in xenograft model (Figure R14). This correlates with the 
observation that diabetic patients treated with metformin have less tumor 
incidence compared with insulin-treated patients (Bowker et al., 2006, Singh 
et al., 2013), and that metformin can inhibit hepatoma cells growth in vitro 
(Chen et al., 2013). In fact, currently there are several clinical trials in progress 
to assess the efficacy of metformin in cancer treatment and prevention. 
Additionally, p38α has a pivotal role in cancer development. In particular, 
deletion of p38α in hepatocytes enhances DEN-induced HCC development, 
underlying its protective role in liver tumorigenesis (Hui et al., 2007). 
Moreover, human HCC frequently shows reduced levels of phosphorylated 
p38α; also, expressing a constitutive active form of p38α in hepatoma cell 
lines induces apoptosis (Iyoda et al., 2003). In contrast, Rudalska et al. 
demonstrated that Sorafenib resistance in HCC could be reverted by p38α 
inhibition in Ras-induced tumors (Rudalska et al., 2014). The differences 
observed in the effect of p38α activation could be explained by differences in 
the experimental model used, genetic versus chemical-induced HCC, and that 
Sorafenib treatment itself could induce specific mutations that would in turn 
affect tumor behavior. Further analysis is necessary to verify if FKO tumors are 
resistant to Sorafenib. In conclusion, we propose that adiponectin-mediated 
inhibition on HCC growth occurs through the activation of AMPKα, which in 
turn activates, directly or indirectly, p38α inducing tumor growth inhibition. It 
would be interesting to test whether adiponectin-induced AMPKα/p38α 
signaling would increase Sorafenib response of resistant HCC. 
1.6 Adipose tissue RNAseq reveals TRAIL as another mediator in 
tumor protection 
JNKs protein targets are multiple and mediate diverse functions (Davis, 2000). 
The first data that emerged from the analysis of adipose tissue RNA-seq 
performed using the Ingenuity® Pathway Analysis (IPA) platform was that the 
majority of the pathways down regulated in FKO adipose tissue 8 months after 
DEN injection were related with liver diseases and malignancies (Figure R15). 
This result is partially biased by the analysis system itself; in fact, IPA is based 
on published data - independently of the tissue in which the study has been 
originally held. It is clear that adipose tissue has been less studied than liver 
and liver diseases. However, among the over-expressed molecules in FKO 
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adipose tissue, we found three secreted proteins that have a known role in 
cancer protection (Figure R16). Among them, TRAIL particularly attracted our 
attention due to its ability to selectively recognize and induce apoptosis in 
cancer cells (Ashkenazi et al., 1999). Moreover, it has been described that 
TRAIL can promote apoptosis in cancer cells through p38α activation (Azijli et 
al., 2013).  This correlated with the higher phosphorylation of p38α in livers 
from FKO mice 15 days and 1 month after DEN injection (Figure R12B, C and 
Figure R17A, B). In addition, tumors from FKO mice present lower levels of 
FLIP in comparison with tumors from FWT mice (Figure R18A, B). Further 
analyses are needed to understand the role of TRAIL in this HCC model; 
however we can hypothesize that high levels of TRAIL can trigger apoptosis in 
FKO tumors.  
In conclusion, our data demonstrated that JNK1 in adipose tissue plays an 
important role in HCC development, controlling both adiponectin and TRAIL 
production (Figure D1). These results highlighted the importance of adipose 
tissue to liver crosstalk during HCC development. Finally, our results indicate 
that the signaling pathway adiponectin/AMPKα/p38α can inhibit HCC 
proliferation and, together with TRAIL-induction of apoptosis, results in 
reduced tumor development, suggesting this molecules in combination as a 
potential treatment for HCC.  
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Figure D1. Schematic representation of the role of JNK1 in adipose tissue-liver crosstalk 
during HCC development. 
JNK1 depletion in adipose tissue induces increase in circulating levels of adiponectin and 
TRAIL. Adiponectin and TRAIL promotes p38α activation in liver, avoiding hepatocytes 
proliferation and triggering tumor cells apoptosis. 
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2. ROLE OF PPARα ACTIVATION IN LIVER CANCER 
2.1 PPARα activation is necessary for HCC development during 
obesity 
PPARα is a transcription factor that plays a pivotal role in sensing metabolic 
changes and inducing fatty acids transport and oxidation (Pawlak et al., 2015). 
It has been shown that PPARα activation protects against steatosis and obesity-
induced liver inflammation (Stienstra et al., 2007, Ip et al., 2003). However, its 
role in HCC development is controversial (Zhang et al., 2014, Peters et al., 
1997). We did not find any significant difference either in body weight or in 
DEN-induced HCC development under normal chow diet condition between 
Ppara-/- and WT mice (Figure R19). However, HFD-fed Ppara-/- mice were 
protected against both HFD-induced obesity and DEN-induced 
hepatocarcinogenesis compared with WT mice (Figure R20), underlying a role 
of PPARα in HCC development. Last year, Gao et al. described the impact of 
PPARα in genetic-induced obesity (Gao et al., 2015). These authors described 
that Ppara-/-ob/ob mice become more obese than ob/ob mice. Additionally, 
Ppara-/-ob/ob treated with Wy-14643, a PPARα agonist, show the same hepatic 
tumor incidence as ob/ob control mice, but less than Wy-14643 treated ob/ob 
mice (Gao et al., 2015). However, Wy-14643 induces the same tumor 
development in WT as in ob/ob mice, indicating that in this model, tumor 
development depends on response to peroxisome proliferator Wy-14643 and is 
independent of obesity. Using a different model we were able to show that 
PPARα contributes to obesity-induction in mice fed a HFD and in this scenario, 
PPARα promotes DEN-induced HCC development. Moreover, DEN-treated 
HFD-fed Ppara-/- displayed a significant increase in survival (Figure R20E) and 
no differences in body weight compared with no DEN-treated HFD-fed Ppara-/- 
(Figure R20B), indicating less physical distress and cachexia, probably linked 
with a decrease in HCC development (Figure R20B, C). However, upon partial 
hepatectomy, we did not observe differences in liver regeneration between 
HFD-fed Ppara-/- and WT mice (Figure R21B, C) indicating that these mice have 
no defects in proliferation induced by liver resection. Nevertheless, HFD-fed 
Ppara-/- mice showed an increase in mortality after partial hepatectomy (Figure 
R21C), probably due to PPARα role in the inflammatory phase of wound healing 
DISCUSSION 
2. ROLE OF PPARα ACTIVATION IN LIVER CANCER 
132 
 
(Michalik et al., 2001) after surgery. Taken together, these results indicate a role 
for PPARα activation in HCC development, strictly during obesity and not in 
normal diet. Moreover, the mechanism involved in PPARα-induced HCC does 
not affect liver regeneration, indicating that lack of PPARα does not influence 
cell cycle entrance and progression in hepatocytes. 
2.2 Ppara-/- mice are protected against DEN-induced liver damage 
Compensatory proliferation after hepatocytes death is the most important 
mechanism that triggers liver cancer development (Baffy et al., 2012). After an 
acute dose of DEN, we observed enhanced cellular damage in livers from HFD-
fed WT mice, but not in HFD-fed Ppara-/- mice, as indicated by AST and ALT 
circulating levels (Figure R22B, C). Moreover, Ppara-/- livers showed less 
apoptosis (Figure R23A) and less activation of signaling molecules involved in 
proliferative response (Figure R23B). However, livers from HFD-fed Ppara-/- 
mice did not produce less pro-inflammatory cytokines; on the contrary, they 
presented more circulating levels of chemokines (CCL3, CCL4 and MCP1) 
(Figure R24), which correlates with higher tumor infiltration (Figure R25). HCC 
is a classic model of inflammation-linked malignancy, however in HFD-fed 
Ppara-/- mice higher levels of inflammation and infiltration are associated with 
less liver damage and less HCC development; furthermore, lipid peroxidation is 
reduced in livers from HFD-fed Ppara-/- mice (Figure R26). In the obese state, 
the levels of circulating FFA are increased. FFA stimulates PPARα activation 
(Memon et al., 2000), inducing lipid peroxidation and consequently ROS 
formation, increasing DNA damage in DEN-stimulated hepatocytes (Caldwell et 
al., 2004). Together, these results suggest a cell-autonomous role of PPARα in 
HCC development during obesity.  
2.3 PPARα induces HCC development in HFD in a cell-autonomous 
way 
A part from its role in hepatic metabolism, PPARα exerts an important anti-
inflammatory function, controlling the production of pro-inflammatory cytokines 
and repressing NF-κB signaling (Poynter and Daynes, 1998, Staels et al., 
1998). However, the results obtained in bone marrow transplantation 
experiments confirm that PPARα activation in hepatocytes, but not in immune 
cells, triggers HCC development in HFD-fed mice. In fact, our results showed 
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that, independently from the donor bone marrow genotype, HFD-fed Ppara-/- 
recipient mice were protected against hepatocarcinogenesis (Figure R27B). 
These data further demonstrate the cell-autonomous role of PPARα in 
hepatocytes during HCC development.  
2.4 PPARα activation induces uncontrolled proliferation  
To elucidate the molecular mechanism underlies the phenotype observed in 
HFD-fed Ppara-/- mice, we analyzed signaling pathways involved in 
tumorigenesis. We observed a reduction in ERK and AKT activation in Ppara-/- 
liver and tumor tissues, which are important for proliferative and pro-survival 
response (Figure R28). Moreover, chronic DEN treatment induced p53 loss in 
tumor and liver tissues from HFD-fed WT mice, whereas in Ppara-/- mice its 
expression was maintained (Figure R28). p53 is an important tumor suppressor 
and it is frequently lost or mutated in the first stages of tumor development, 
inducing cell dedifferentiation and uncontrolled proliferation (Tschaharganeh et 
al., 2014). Additionally, the expression of other cell-cycle regulatory genes was 
increased in Ppara-/- tumors compared with WT, whereas mRNA levels of genes 
important in cell-cycle progression were reduced in livers from Ppara-/- mice 
treated with DEN (Figure R29). These results indicate a reduction in 
proliferative signaling not only in tumors from Ppara-/- but also in surrounding 
liver, which is the tissue that can generate more tumors. Moreover, loss of p53 
expression in both, livers and tumors, in DEN-treated WT mice but not in Ppara-
/- ones points out that activation of PPARα primes hepatocytes to increased 
proliferation. We hypothesized that increased PPARα activation due to obesity 
induces lipid peroxidation and ROS production. The mutational ratio is 
enhanced by ROS, causing p53 loss or mutation and dysregulation of cell-cycle 
regulators. Together these events provoke uncontrolled proliferation and 
activation of pro-survival signaling pathway. These data are consistent with a 
recently published work that recognized PPARδ, another nuclear receptor, as 
the link between obesity and colon cancer (Beyaz et al., 2016). 
2.5 PPARα hyperactivation promotes liver cancer 
It has been described that JNK1 and JNK2 suppress PPARα activation in 
hepatocytes (Vernia et al., 2014) and lack of both JNKs results in constitutively 
active PPARα. To further confirm the major role of PPARα activation in liver 
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cancer development, we used hepatocytes-specific Jnk1 and Jnk2 knock out 
mice. These mice spontaneously developed cholangiocarcinoma at 14 months 
of age, with an incidence of 94% (Figure R31A, B). They showed enhanced 
liver damage, as demonstrated by ALT levels (Figure R31C). The differences 
observed in the type of liver cancer in the two models might be a consequence 
of the tumorigenic stimuli. In fact, DEN induces hepatocytes compensatory 
proliferation in response to massive hepatocytes death. However, in absence of 
a damaging stimulus the most proliferative cells in the liver are bile duct cells. 
Taken together our results demonstrate that PPARα activation plays an 
important role in liver cancer development and that its influence is cell-
autonomous. In fact it triggers hepatic lipid storage and peroxidation, inducing 
ROS production, loss of p53 expression and enhancing uncontrolled 
proliferation (Figure D2). Additionally, we demonstrated that PPARα activation 
together with liver damage enhanced hepatocytes compensatory proliferation 
inducing HCC development, while in absence of a damaging stimulus it 
increases proliferative rate of bile duct cells resulting in cholangiocarcinoma 
formation. PPARα activators, as fibrates, have been introduced as therapy for 
obesity and NAFLD. Our results pointed out that these therapies could be 
dangerous for patients, and further studies would be necessary to assess their 
safety. 
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Figure D2. Schematic representation of the role of PPARα activation in liver cancer. 
Obesity increases circulating free fatty acids inducing PPARα activation in hepatocytes. PPARα 
promotes lipid peroxidation, which in turn increases ROS production. On one hand ROS 
induces DNA damage and uncontrolled proliferation due to loss or mutation of p53 and other 
cell cycle regulators. On the other hand, ROS provokes cellular damage that triggers 
compensatory proliferation. 
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1. ND-fed FKO mice are protected against hepatocellular carcinoma 
development  
2. JNK1 in adipose tissue does not affect liver regeneration after partial 
hepatectomy  
3. ND-fed FKO mice present no changes in functionality or infiltration in adipose 
tissue 
4. JNK1 in adipose tissue controls adiponectin circulating levels, which in turn 
inhibits liver cancer development through AMPKα and p38α activation 
5. TRAIL expression in the adipose tissue is controlled by JNK1 and could be a 
good candidate for hepatocellular carcinoma treatment 
6. Activation of PPARα by high fat diet triggers hepatocellular carcinoma 
development  
7. Lack of PPARα reduces hepatectomy-survival rate but does not affect liver 
regeneration on high fat diet fed mice 
8. PPARα activation during obesity increases chemical-induced liver damage 
and compensatory proliferation 
9. PPARα activation in hepatocytes but not in immune cells promotes 
hepatocellular carcinoma development 
10. PPARα activation through Jnk1 and Jnk2 deletion in hepatocytes triggers 
liver cancer development 
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1. JNK1 en el tejido adiposo induce el desarrollo del carcinoma hepatocelular 
en ratones alimentados con dieta normal pero no en ratones alimentado con 
dieta grasa 
2. JNK1 en tejido adiposo no tiene efectos sobre la regeneración hepática tras 
la hepatectomía parcial  
3. La expresión de JNK1 en el tejido adiposo en dieta normal no influye en la 
funcionalidad ni en la infiltración del tejido adiposo  
4. JNK1 controla los niveles circulantes de adiponectina, que a su vez inhibe el 
desarrollo del carcinoma hepático a través de la activación de AMPKα y de 
p38α  
5. La expresión de TRAIL en el tejido adiposo es controlada por JNK1. TRAIL 
podría ser una buena diana terapéutica en el tratamiento del  carcinoma 
hepático 
6. La activación de PPARα en la obesidad induce el desarrollo del carcinoma 
hepático  
7. La carencia de PPARα no afecta a la regeneración hepática, pero reduce el 
ratio de supervivencia en animales alimentados con dieta grasa 
8. La activación de PPARα en la obesidad aumenta el daño hepático y la 
subsecuente proliferación compensatoria 
9. La activación de PPARα en los hepatocitos y no en el sistema inmune 
incrementa el desarrollo del carcinoma hepatocelular 
10. La activación de PPARα eliminando Jnk1 y Jnk2 en los hepatocitos induce 
el desarrollo de colangiosarcoma 
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